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An Assessment of Cognitive and Sensorimotor Deficits Associated with APPsw and 
P301L Mouse Models of Alzheimer’s Disease 
Marcos F. Garcia 
ABSTRACT 
 
 
        Behavioral characterization of animal models for Alzheimer’s Disease is critical 
for the development of potential therapeutics and treatments against the disease. While 
there are several known animal models of AD, three current models--APPsw, P301L, and 
APPsw+P301L--have not been well characterized, if at all. This study, therefore, aimed 
to perform a full behavioral characterization of these three models in order to better 
understand the impairments associated with each one. Between 5 and 8.5 months of age, 
animals were behaviorally tested in a variety of sensorimotor, anxiety, and cognitive 
tasks. The number of tau+ neurons in the forebrains of P301L mice was then compared to 
their behavioral performance.  
Results of this study indicate that retinal degeneration (rd) seriously impairs the 
performance of mice in behavioral tasks. Animals that carry the homozygous allele of 
this mutation must, therefore, be eliminated from any such study requiring visual acuity. 
After this elimination, my findings indicate that APP mice are impaired in several 
cognitive tasks (including platform recognition, Morris maze, Y-maze, and radial-arm 
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water maze) at a young early age (5 to 8.5 months of age). These mice have fairly normal 
sensorimotor function, showing significant impairment only in balance beam 
performance starting at 5 months. Although P301L mutant Tau mice, as a group, did not 
have significant impairments in any sensorimotor or cognitive task, correlation analysis 
revealed that higher numbers of tau+ neurons in cortex and hippocampus were associated 
with poorer cognitive performance.  Finally, discriminant function analysis (DFA) 
appears able to accurately discriminate between the three transgenic groups of mice using 
only an 8-measure data set.  
In conclusion, this study provides the first comprehensive, multiple task 
behavioral assessment of the APPsw and P301L animal models of AD, indicating that 
APPsw mice are cognitively impaired at an early age while P301L mice are largely 
unimpaired through 8.5 months. Nonetheless, correlational analysis implicates the 
formation of neurofibrillary tangles in the onset of cognitive impairments. Finally, my 
findings recommend the continued use of DFA to determine if groups of animals, based 
on different transgenicity or therapeutic treatment, could be discriminated between from 
their behavior alone.  
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Introduction 
 Alzheimer’s disease (AD) is widely considered to be the most prevalent form of 
dementia, occurring primarily in mid to late- life. Statistics indicate that AD affects up to 
10% of all individuals over the age of 65 and 40% of those over the age of 80. Overall, 
AD accounts for approximately 81% of all cases of dementia. As life expectancies 
continue to increase worldwide due to advances in medical treatment, the number of AD 
cases is expected to rise dramatically over the next 50 years (Janus and Westaway, 2001). 
Therefore, the development of therapeutics to combat AD and alleviate its symptoms is 
becoming more critical with each passing year.  
AD is characterized by progressive memory impairment, disordered cognitive 
function, and a progressive decline in language function. The time-course for AD in 
affected individuals can last between 2 to 20 years. Typically, the first symptoms related 
to AD are moderate losses in working memory and language function accompanied by 
mild depression. As the disease progresses, the deficits in working memory and language 
function become more severe and long-term memory begins to be affected. Lastly, the 
final stages of AD are characterized by a virtually complete loss of memory and intellect, 
leaving the patient in a bedridden, vegetative state that ultimately results in death. 
Researchers have already identified what many refer to as the two “pathological 
hallmarks” of AD—the formation of neuritic plaques and neurofibrillary tangles. Neuritic 
plaques are small patches composed of amyloid protein that sticks to neurons and attracts 
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microglia as well as astrocytes. The formation of these plaques leads to neuronal death, 
primarily in areas of the limbic and association cortices. Neurofibrillary tangles (NFT’s) 
are created when tau, a normal, microtubule-associated protein found in most neurons, 
becomes hyperphosphorylated to form paired helices that disrupt axonal conduction and, 
ultimately, results in the death of the neuron. NFT’s can be found in the entorhinal cortex, 
hippocampus, parahippocampal gyrus, amygdala, frontal, temporal, parietal, and occipital 
association cortices of AD patients. While these two lesions represent the hallmark 
pathologic characteristics of AD, neuritic plaques and NFT’s can occur independently of 
each other in AD as well as in other, less common neurodegenerative diseases (Selkoe, 
2001). 
 
Amyloid Precursor Protein 
 As previously mentioned, neuritic plaques, one of the two hallmarks of AD 
pathology, are composed primarily of amyloid protein that becomes deposited in the 
brain. Specifically, it is b-amyloid, or Ab , that is principally responsible for the formation 
of these neuritic plaques. Ab , a protein composed of either 40 or 42 amino acids is, itself, 
synthesized from a much larger parent protein named amyloid precursor protein, APP. 
APP is a protein comprised of 695-751 amino acids that is commonly found in the 
membranes of neuronal cells throughout the brain and central nervous system (Selkoe, 
2001). The APP protein contains three principal sites where proteolytic enzymatic 
cleavage can take place that is critical to the ontogeny of AD. Cleavage by a-secretase at 
amino acid 687 results in two harmless APP subunits, APPs-a and C83. Cleavage of APP 
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at amino acids 671 and 711/713 by b-secretase and g-secretase, respectively, results in the 
release of the cytotoxic Ab40 and Ab42 peptides, which are deposited.  
Generally, it is thought that Ab42 begins the process of plaque development by 
forming loose aggregates (diffuse deposits). This complex later attracts Ab40, forming a 
much denser, more compact plaque (Selkoe, 2001). As Ab  is deposited and begins to 
form fibrils, microglia, the brain’s phagocytic cells, are attracted to the plaque site and 
become activated. These activated microglia, which carry receptors for Ab , are thought to 
assist in clearing Ab  from brain tissue (Yan et al., 1996; Ard et al., 1996). However, 
activated microglia are a two-edged sword in that they also respond to Ab-activated 
complement by secreting toxic agents such as free radicals and harmful proteases. 
(Rogers et al., 1992). Activated microglia also release cytokines, such as IL-1 and TGF-
b , which serve to activate astrocytes and attract them to the locations of Ab  plaques. 
These activated astrocytes then trigger the release of two inflammatory mediators, 
Apolipoprotein E (ApoE) and anti-chymotrypsin (ACT). ACT, an acute-phase 
inflammatory protein that is over-expressed in astrocytes that surround Ab  plaques, is 
thought to promote further deposition of Ab and formation of more mature plaques 
through direct molecular interaction with Ab  (Nilsson et al., 2001). ApoE, a 299-amino 
acid lipid transport protein, is also thought to play a role in AD pathogenesis by 
mediating the conformational transition of Ab  into b-pleated sheets, which further 
promotes deposition (Holtzman et al., 1999; Wisniewski et al., 1992).  
Researchers have come to understand that, as people age, levels of deposited brain 
Ab  increase, enhancing the risk of developing Alzheimer’s Disease. While this increase 
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generally occurs in mid-life or later, some individuals experience an increase in Ab  at a 
much earlier age, leading to onset of AD symptoms. While the mechanisms that lead to 
this increase in brain Ab  are not fully understood and could involve age-related 
reductions in Ab  breakdown or clearance from the brain, certain mutations have been 
identified that are purported to enhance b-secretase and/or g-secretase activity, increasing 
the likelihood that Ab  will result in the brain. One such mutation occurs on the 
presenilin-1 protein (PS-1) and has been thought to significantly increase the activity of 
g-secretase (Selkoe, 2001). While the exact mechanism of PS-1 action with regards to g-
secretase has yet to be elucidated, two general theories have been developed to describe 
its potential function. Some researchers have suggested that PS-1 is a direct co-factor of 
g-secretase and, thus, is required for the normal function of g-secretase. This theory is 
supported by experiments showing that PS-1 “knock-out” mice have deficient g-secretase 
function (De Strooper et al., 1998). The second theory is that PS-1, which serves as a 
membrane-bound protein, may have a role in cell trafficking, controlling the interaction 
of g-secretase with its necessary cofactors. This theory is not widely supported (Naruse et 
al., 1998). Also, point mutations on the APP protein near the b-secretase and g-secretase 
cleavage sites can alter the activity of these enzymes, resulting in greater Ab42 release 
(Selkoe, 2001). Cases of AD in which a genetic mutation is to blame for an increase in 
Ab42 release are referred to as familial AD, so called because it is inheritable through an 
autosomic dominance process and is thus passed down through families. Familial AD 
comprises only 10% of the known cases of AD in individuals. The majority of AD cases, 
~90%, occur through unknown causes and are referred to as sporadic AD (Janus and 
Westaway, 2001).  
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Neurofibrillary Tangles 
 The second pathological hallmark of AD is the formation of neurofibrillary 
tangles within the axons of affected neurons in the brain. These tangles are composed of a 
protein named tau, which is normally bound to axon microtubules. When tau protein 
becomes hyperphosphorylated by unknown kinases, it dissociates from the microtubule 
and forms insoluble, paired, helical filaments. The formation of these paired, helical 
filaments strangles the axon, eventually killing it and preventing any downstream 
communication (Selkoe, 2001). Recently, it has been concluded that tangle formation can 
be induced by Ab-mediated phosphorylation of the tau protein, propagating the theory 
that amyloid deposits and NFTs may act in concert to generate AD pathology (Götz et al., 
2001). In addition to AD, NFT formation has also been linked with other less common 
neurodegenerative diseases such as frontal temporal lobe dementia, Kuf’s Disease, and 
sclerosis panencephalitis (Selkoe, 2001). 
 
Transgenic Mouse Models of Alzheimer’s Disease 
 In order to better understand the mechanisms underlying AD and test potential 
therapeutics against the disease, transgenic mouse models are needed. Transgenic mouse 
models are generated by inserting either wild-type or mutant AD transgenes into the 
genome of a fertilized egg. Specific promoters, such as PDGF1-b  (Games et al., 1995), 
PrP (Hsaio et al., 1996), and thy-1 (Sturchtery-Pierrat et al., 1997), are used to ensure that 
the desired mutation is expressed in the brain. When the litter is born, the progeny are 
genetically screened to select only the mice that carry the mutation. In this way, we may 
observe the effects of particular genes of interest in the pathophysiology of AD.  
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One particular mutation that results in an increased release of toxic Ab42 is the 
Swedish mutation (APPsw), so named because it was discovered in a large Swedish 
family that suffers from familial AD. The APPsw mutation is a double point mutation 
that occurs at amino acids 670 and 671 of the APP protein, where a lysine residue is 
changed to asparagine and methionine is replaced by leuc ine, respectively. The APPsw 
mouse model is generated using a hamster prior protein (PrP) promoter that expresses the 
mutation in neurons of the brain. The combination of these two mutations on the APP 
protein is thought to increase the activity of b-secretase, creating a greater likelihood that 
Ab40 and Ab42 will be released (Selkoe, 2001). 
In addition to the APPsw mutation, the V717F point mutation on the APP gene, 
also called the PDAPP mutation, is known to cause an increase in Ab42 release. 
Transgenic mice that carry this mutation over express a mutated human APP minigene 
that is driven by the platelet-derived growth factor promotor. The result of this mutation 
is increased g-secretase activity, which leads to greater cleavage at the carboxy terminus 
of the Ab  protein (Dodart et al., 2000). 
 As mentioned previously, mutations to the PS1 protein, which participates in the 
g-secretase complex, also result in a greater release of Ab42, apparently by increasing the 
activity of g-secretase (Selkoe, 2001). Two such mutations, M146L or M146V, are 
currently employed in transgenic mice, under control of the PDGF-b2 promotor. When 
either of these PS-1 mutations are combined with the APPsw mutation in transgenic 
mice, commonly called the PSAPP model, Ab  production is further enhanced (Duff et al., 
1996; Holcomb et al., 1998), resulting in enhanced and earlier Ab  deposition.   
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 Mutations to the tau protein can also promote AD pathology, notably NFT 
formation intraneuronally. In addition to AD, NFT formation prominently found in 
several other neurodegenerative disorders (collectively known as “tauopathies”): 
progressive supranuclear palsy (PSP), corticobasal ganglionic degeneration (CBD), and 
frontotemporal lobe dementia (FTD). FTD, the most common of these disorders, involves 
impaired social conduct, diminished speech leading to muteness, and progressive 
dementia in affected patients (Kwon, 2002). There are three such point mutations to the 
tau protein that are commonly used in transgenic mouse models of AD: P301L controlled 
by the mouse prion protein promotor (MoPrP), V337M, under the expression of the 
PDGF-b  promotor, and R406W, under control of the CaMK-II promotor. All of these 
mutations are capable of generating NFT’s when overexpressed in transgenic mice. Each 
of these models, however, differ in their temporal sequence and regional distribution of 
NFT formation, as will be discussed later.  
 In the following pages, I will attempt to summarize the current literature 
describing transgenic mice carrying these different mutations that produce Alzheimer’s-
like pathophysiology. In particular, I will be discussing the principle behavioral and 
pathological findings from these studies in order to provide a reasonable assessment of 
what is currently known in the field of Alzheimer’s transgenics with regard to these 
mutations.  
 
APPsw Model: Pathology and Brain Ab  levels 
 The first study to examine the APPsw mouse model of AD was authored by Hsaio 
et al. (1996). In this study, the authors determined, through ELISA, that transgenic mice 
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between 11 and 13 months of age have, on average, 5 times more Ab40 in their brains 
than transgenic mice between the ages of 2 to 8 months. Likewise, the oldest group of 
transgenic mice was also found to have 14 times more brain Ab42 than mice in the 2-8 
month-old group. Of the three Tg+ mice in the 11 to 13 month-old age group that 
underwent neurochemical analysis, all three were found to possess classic senile plaques, 
including dense amyloid cores, as well as diffuse deposits of Ab .  These deposits were 
limited to frontal, temporal, and entorhinal cortices, as well as the hippocampus, 
presubiculum, subiculum, and cerebellum. The densest amyloid cores were found in the 
cortex, subiculum, and presubiculum. Amyloid deposits were absent in all of the non-
transgenic mice analyzed in this study, as well as APPsw mice in the 2-8 month age 
range.  
A study conducted by Irizarry et al. (1997) found that Tg2576 mice at 16 months of 
age, bearing the APPsw mutation, possess extensive Ab  deposits in the molecular layer 
of the hippocampus, the cortex, and the amygdala. Specifically, the authors determined 
that the CA1 region of the hippocampus, dentate gyrus, cingulate cortex, and entorhinal 
cortex possessed an average amyloid burden of between 3.6 to 8.5%, as determined 
through an immunostain using the R1282 polyclonal antibody. As expected, none of the 
non-transgenic subjects demonstrated any Ab  immunoreactivity. Despite these moderate 
levels of Ab in and around the hippocampus, the study concluded that Tg+ mice did not 
differ significantly from Tg- test subjects in the number of neurons in the CA1 region of 
the hippocampus. This finding is particularly interesting since the hippocampus 
undergoes extensive neuronal loss in the course of human AD and is thought to be 
associated with behavioral deficits in mice. These results suggest that behavioral deficits 
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incurred by APPsw transgenic mice might be the result of APP overexpression or the 
abundance of small Ab  assemblies, rather than hippocampal cell loss.  
 In a similar study, Calhoun et al. (1998) examined a group of 14-18 month-old 
APP23 mice expressing the Swedish mutation, but with a different promotor from 
Tg2576 mice. Like Irizarry et al. (1997), Calhoun et al. (1998) found that these mice 
possessed a large number of deposited Ab  plaques in the neocortex and hippocampus. 
According to the study, at least 90% of plaques contained dense, fibrillar amyloid cores, 
similar to the kind found in human cases of AD. In addition, vascular amyloid was 
detected, primarily in the meningeal, neocortical, and thalamic vessels. In contrast to the 
Irizarry et al. (1997) study, however, Calhoun et al. (1998) found that Tg+ mice showed a 
significant decrease in the number of CA1 neurons when compared to their Tg- 
counterparts. Specifically, the study indicated that Tg+ mice exhibited a 14% reduction in 
the number of CA1 neurons, with some animals possessing a particularly high plaque 
load losing up to 25% of CA1 neurons. In general, the authors found that CA1 neuron 
loss was directly proportional to Ab  plaque load. This finding challenges the observation 
made by Irizarry (1997), stating that no appreciable CA1 neuronal loss is evident in Tg+ 
mice possessing a high Ab  plaque load. In the neocortex, however, Calhoun et al. (1998) 
found no evidence of global neuronal loss and suggest that the neocortical neurons are 
simply being physically displaced. 
 A study by Frautschy et al. (1998) examined a group of 10-16 month-old Tg2576 
mice bearing the APPsw mutation to observe the relationship between plaque formation 
and microglial activation. The study found that Tg+ animals possessed clusters of 
microglia surrounding Ab  deposits, while Tg- animals had no such microglial clusters. In 
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addition, it was observed that subjects containing small Ab  deposits showed only a few 
or no activated microglia, while those who had larger Ab  deposits had greater amounts of 
activated microglia. Further, the authors discovered that the Ab40 antibody was more 
successful at staining activated microglia than the Ab42 antibody, suggesting that Ab40, 
and not Ab42, may be primarily responsible for initiating the microglial response in the 
entorhinal and occipital cortex and the hippocampus. This theory is confirmed by 
evidence obtained in previous studies indicating that, by 11-12 months of age (the 
approximate time when microglia begin to show activation in the onset of AD), 60% of 
Ab  plaques in Tg2576 mice are composed of Ab40. 
To identify the role of Ab  deposition in the formation of oxidative free radicals in 
the brains of mice, Pappolla et al. (1998) studied groups of Tg2576 mice at 4 months and 
21-25 months of age. These mice were sacrificed and immunostained for markers of 
oxidative damage in the brain, specifically, CuZn superoxide dismutase (CuZnSOD) and 
heme-oxygenase-1 (HO-1). In addition, the authors also stained for Ab and ubiquitin, 
using specific monoclonal antibodies. The authors found that, at 21-25 months of age, the 
Tg+ mice displayed extensive signs of oxidative damage colocalized to regions of the 
brain where Ab  plaques were found. Further, these regions of the brain with plaque 
staining and oxidative markers were also found to stain for ubiquitin, an indicator of free-
radical-mediated cytotoxicity. In contrast, 4 month-old Tg2576 mice showed no signs of 
oxidative markers or Ab  plaques. Older Tg- mice, 21-27 months of age, likewise, failed 
to demonstrate any Ab  plaques or oxidative markers. These findings promote the theory 
that Ab  plaque deposition and free radical- induced cell death in the brain are temporally 
linked. An in vitro cell culture study performed by Pappolla et al. (1998) further 
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implicates Ab  in the formation of free radicals. In their experiment, the authors cultured 
PC12 cells in the presence of Ab25-35, and observed that these cells underwent rapid cell 
death and demonstrated the presence of oxidative markers.  
Benzing et al. (1999) examined a set of ten Tg2576 mice carrying the APPsw 
mutation and found that they begin to show moderate amounts of Ab  deposits at 12 
months of age and considerable deposition by 18 months. At the 18-month time point, 
most of these deposits occurred in the temporal cortex, where plaques covered 24% of the 
cortical surface area. Ab  plaques were also extensively found in the fronto-parietal lobe, 
where 16% of the surface area was covered in plaques, and the hippocampus, which 
demonstrated 10% surface coverage by plaques. Of the plaques found in the temporal and 
fronto-parietal lobes, approximately 3% was found to be compact in nature, while about 
6% of the hippocampal plaques were similarly constituted. Interestingly, at the 12-month 
time point, the cortical surface coverage of Ab  plaques was considerably less, while the 
relative percentage that is compact stayed the same.  
 Through the use of immunostaining, Benzing et al. (1999) also discovered that the 
majority of fibrillar Ab  plaques in 12 and 18 month-old mice were closely accompanied 
by activated microglia, the macrophages of the brain. These activated microglia were 
found to contain IL-1b  and TNFa, two immune cytokines. In addition, IL-6, another 
immune cytokine, was found in activated astrocytes surrounding fibrillar Ab  plaques at 
both the 12 and 18-month time point. These two findings, taken together, serve to 
confirm the role of the neuroinflammatory processes in the pathogenesis of human AD.  
 Another set of Tg2576 mice with the APPsw mutation was studied by Mehlhorn 
et al. (2000). In the study, the mice were shown to be free of fibrillar Ab  plaques in the 
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hippocampus and cerebral cortex until approximately 14 months of age, despite 
expressing the mutant APP mRNA as early as 2 months of age. Even at 14 months, 
however, the Ab  plaque load is minimal. Immunostaining of the brains of these mice 
revealed a large number of reactive astrocytes surrounding the newly developed fibrillar 
Ab  plaques in the cerebral cortex at the 14-month time point. These astrocytes were 
found to contain active forms of IL-1b  and glial fibrillary acidic protein (GFAP), a 
marker for astrocytes. Immunocytochemistry performed on sections of cerebral cortex at 
the 12 and 13-month time points revealed no detectable IL-1b in Tg2576 mice, 
suggesting that fibrillar Ab  deposition is required for astrocytes to become activated. In 
addition, a multiple-probe ribonuclease protection assay performed on the frontal, 
parietal, occipital, and entorhinal cortices of 2-13 month-old Tg2576 mice failed to detect 
the induction of any pro- inflammatory cytokine mRNA, indicating the lack of any 
inflammatory response prior to Ab  deposition. These two findings seem to indicate that 
the deposition of Ab  and the formation of fibrillar Ab  plaques are needed to trigger the 
release of pro- inflammatory cytokines and induce the activation of reactive astrocytes.  
 Kawarabayashi et al. (2001) indicates that the amount of detergent insoluble Ab  
shows a rapid increase in Tg2576 transgenic mice starting at around 6 months of age. 
These levels of insoluble Ab  in the brain continue to increase rapidly from 6-10 months, 
eventually leading to the formation of Ab  plaques by 9-12 months of age. Detergent 
soluble Ab  is present throughout life.  
 In summary, the current literature indicates that mature Ab  plaques begin to form 
in the cortex and hippocampus of Tg2576 as early 9-12 months of age. Ab  deposition 
within plaques appears to cause the activation of astrocytes and microglia as well as the 
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concomitant release of inflammatory cytokines. While the direct role of Ab  in initiating 
hippocampal cell death is still a point of contention, it appears that the rise in insoluble 
levels of Ab  by 6-7 months is certainly implicated in the onset of several potentially 
destructive changes in the brains of these transgenic mice, such as free radical formation 
and initiation of the inflammatory response.   
  
APPsw Model: Behavioral Findings 
 In the first study to assess the extent to which mice transgenic with the APPsw 
mutation exhibit a loss of behavioral function, Hsaio et al. (1996) tested Tg+ and Tg- 
mice in the Y-maze at 3 and 10 months of age, and the Morris Water Maze at 2, 6, and 9-
10 months of age. The authors found that the Tg+ mice showed no behavioral deficits 
compared to their Tg- counterparts up to 10 months of age. At 10 months, however, the 
Tg+ mice were found to be impaired in their ability to spontaneously alternate between 
the three arm choices in the Y-maze. Age-matched control mice demonstrated a 
significantly greater percent alternation at the 10-month time point than their Tg+ 
counterparts. Arguably, however, Tg+ mice were already performing at chance levels at 3 
months and, in that context, were impaired early in this task. 9-10 month-old mice also 
showed impairment, compared to age-matched controls, in their ability to locate a 
submerged platform in the Morris Water Maze task. The Tg+ mice required a 
significantly greater amount of time to locate the hidden platform on each of the 6 days of 
acquisition at 9-10 months, but not at earlier time points. With the hidden platform 
removed following the 6-day spatial acquisition period, the mice were returned to the 
pool, wherein their swim path was observed and recorded. It was determined that 9-10 
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month-old Tg+ mice spent significantly less time in the target quadrant (which previously 
held the platform) than their Tg- counterparts. However, Tg+ mice at 9-10  months did 
not spend significantly less time in the target quadrant than younger Tg+ mice at 3 and 6 
months. Nonetheless, these 9-10 month-old Tg+ mice made far fewer crossings over the 
prior location of the hidden platform than their non-transgenic littermates. Some Tg2576 
mice were later re-tested in the water maze, with spatial cues rearranged, at 12-15 months 
of age. Once again, the Tg+ group continued to show significant impairment in both 
escape latency and time spent in the goal quadrant when compared to Tg- mice, although 
none of this data at 12-15 months was presented. As discussed previously, Hsaio et al. 
(1996) found that these Tg2576 mice undergo a rapid increase in levels of Ab40 and Ab42 
between 2-8 months and 11-13 months of age. Taken together, it appears that the 
behavioral deficits demonstrated by these Tg2576 mice could be related to the increase in 
brain Ab  levels/deposition.  
A study conducted by Holcomb et al. (1998) focused on the differences between 
APPsw single transgenic mice and APPsw/PS-1 doubly transgenic mice in behavior and 
pathology. When Ab  load was compared between these two transgenic lines, the authors 
discovered that the doubly transgenic mice experienced a significant increase (p<0.001) 
in Ab42 and Ab40 from 6 weeks of age to 24-32 weeks of age while the APPsw mice 
showed no significant change in the amount of either Ab  species through the same time 
period. Consequently, by 24-32 weeks of age, the APPsw/PS-1 mice have a significantly 
greater level (p<0.001) of Ab40 and Ab42 than age-matched APPsw mice. This increase in 
Ab42 for the APPsw/PS-1 mice began before the mice reached 12 weeks of age and was 
followed by a second, more substantial increase in Ab  load between 12-16 weeks and 24-
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32 weeks of age. Testing in the Y-maze indicated that APPsw single transgenic mice and 
APPsw/PS-1 doubly transgenic mice showed similarly lower percent alternations at 12-
14 weeks than either the PS-1 single transgenic group or the Tg- control group. These 
findings seem to indicate that the APPsw mutation, and not the PS-1 mutation, is 
primarily responsible for generating the Y-maze impairment. Also, it appears that this 
impairment is unrelated to the formation of Ab  plaques, since the impairment at 12-14 
weeks in APPsw mice occurs long before the onset of Ab  deposition in those mice. When 
these same mice were compared for the number of arm entries made, APPsw/PS-1 mice 
were found to have a significantly greater number of entries than any other transgenic 
group. APPsw and PS-1 transgenic mice were not statistically different from Tg- mice in 
their number of arm entries. Thus, it appears that the effect of the PS-1 mutation in AD 
pathology is to increase the amount of Ab42 in the Alzheimer’s brain, inducing increased 
exploratory behavior/activity prior to the formation of Ab  plaques.  
In a follow-up to this study (Holcomb et al., 1999), the authors re-tested all four 
genotypes of mice in the Y-maze at 6 months and 9 months of age. At the 6-month time 
point, the APPsw/PS-1 and APPsw mice were each found to be impaired in percent 
alternation compared to the PS-1 and Tg- groups. Only the APPsw/PS-1 mice were found 
to have a significantly greater number of arm entries than Tg-, although the APPsw 
groups showed a slightly elevated number of arm entries compared to Tg-. At 9 months, 
only the APPsw/PS-1 group of mice demonstrated any impairment in the Y-maze for 
either arm entries or percent alternation. These impairments are not progressive in nature, 
however, since the APPsw and APP/PS-1 groups were already performing near chance 
levels at 3 months of age. When tested in the Morris Water Maze at 6 or 9 months of age, 
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no impairments were found in any of the transgenic mice for either acquisition or 
memory retention. It is important to note, however, that the Tg- mice performed near 
chance levels at 9 months and actually had a lower percent time in the platform quadrant 
than the APPsw and APPsw/PS-1 groups. The authors failed to address this perplexing 
finding. The conclusions from this study are similar to those reached in the previous 
paper: the APPsw mutation is primarily responsible for the impairment in Y-maze 
alternation while PS-1 serves to slightly enhance AD pathology (perhaps seen here 
through the increase in the number of arm entries) by increasing the production of Ab42. 
None of the Y-maze behavioral changes seem to be related to Ab  deposition, as they pre-
date the onset of plaque formation. 
A study conducted by Westerman et al. (2002) creates a correlational link between 
the onset of spatial acquisition deficits and the appearance of insoluble Ab .  In the study, 
the authors tested four cohorts of animals bearing the APPsw mutation. These animals 
were tested in the Morris Water Maze at various time points from 4 months of age to 25 
months of age. Each animal received a total of 36 acquisition trials, with a probe trial 
performed after each set of 12 acquisition trials to assess the amount of learning. Animals 
with age-independent deficits were eliminated from analysis. The results indicate that, 
prior to 6 months of age, the Tg2576 mice show no impairments in water maze escape 
latency or probe trial when compared to their age-matched controls. Tg2576 mice tested 
at 6-11 months, however, demonstrated lower mean probe trial scores, indicating that 
they spent less time, on average, in the goal quadrant during memory retention trials than 
their Tg- counterparts. Likewise, 12-18 month-old Tg+ and 20-25 month-old Tg+ mice 
showed significantly lower MPS than their age-matched Tg- littermates. Tg- mice at all 
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ages succeeded in scoring higher than chance in memory retention, such that the oldest 
Tg- group was statistically not different from the youngest Tg- group. In the prior 
acquisition phase of this task, 6-11 month-old Tg+ mice were normal compared to 
control. However, 12-18 month-old Tg+ and 20-25 month-old Tg+ mice were impaired 
in the last third of acquisition when compared to Tg-, demonstrating a significantly 
greater latency to locate the hidden platform. Overall, none of the Tg+ mice were 
impaired in acquisition when compared to their age-matched controls. These results were 
even more meaningful when coupled with the fact that Ab insol begins to appear in the 
brains of Tg2576 mice at approximately 6 months of age. Less than 10% of the Tg2576 
mice tested from the 4-5 month-old group contained Ab insol while 70% of the 6 month-
olds and 100% of the 10 month-olds possessed Ab insol. Detergent-soluble Ab  was present 
in all the age groups of Tg2576 mice tested. These results seem to indicate, therefore, that 
Absol has little to no effect in the impairment of spatial memory while Ab insol plays a 
much larger role-perhaps through pathogenic Ab  oligomeric assemblies.  
Westerman et al., (2002) also demonstrated that transgenic mice possessing both the 
APPsw mutation and a mutant form of the PS1 mutation (APPsw/PS1) have a more 
accelerated conversion of Absol to Ab insol. As a result, these “bigenic” mice begin to show 
insoluble amyloid plaques by 3 months of age. Because these mice contain Ab insol at an 
earlier age than APPsw, APPsw/PS1 mutants showed more impaired performance in the 
first probe trial than APPsw or PS1 single transgenic mice. Performance in the second 
and third probe trials for the APPsw/PS1 mice was not significantly different than the 
performance of the APPsw mice because of the steep learning curve associated with the 
particular strain of mice used to breed these transgenes (FVB x 129). In summary, it 
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appears that small Ab  oligomers are mostly responsible for the disruption in water maze 
spatial memory retention of Tg2576 mice (Westerman et al., 2002).  
In addition to the APPsw mutation causing cognitive deficits, a study by Chapman 
et al. (1999) illustrates that the APPsw mutation results in a loss of long-term potentiation 
(LTP) in the hippocampus of affected mice. The authors tested this theory in vitro by 
inducing LTPs in the dentate gyrus and CA1 region of the hippocampus in both Tg+ and 
Tg- mice aged 2-8 months and 15-17 months. LTP induction was accomplished through 
theta-burst stimulation to the Schaffer collaterals and the perforant pathway. For the 15-
17 month-old mice, the authors found that stimulus response in the CA1 and dentate 
gyrus were significantly higher than baseline for the Tg- mice following tetanus but the 
Tg+ mice demonstrated no significant increase in stimulus response. Mice in the 2-8 
month-old group showed no impairments to LTP induction as both the Tg+ and Tg- mice 
demonstrated increased response to stimulus following tetanus. Short-term facilitation 
seemed unaffected in Tg+ mice, as response to the second stimulus in each pulse pair was 
significantly higher than the first in all groups of mice tested. Tests performed on in vivo 
mice confirmed the findings from the in vitro study since LTP induction was impaired in 
APPsw mice at the 13-15 month time-point. When 16-17 month-old mice were observed 
in the T-maze forced-choice alternation task, the study revealed that old APPsw mice 
were significantly impaired compared to their age-matched controls in their ability to 
learn the task. By contrast, 2 month-old APPsw mice learned the task as quickly as their 
age-matched controls and quicker than the 16-17 month-old APPsw mice. Pathological 
observations made after the LTP measurements and T-maze task indicate that the older 
APPsw group of mice possessed high brain levels of Ab , while their non-transgenic 
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counterparts had none. Correlational analysis showed that impaired performance in the T-
maze is associated with loss of LTP induction.  
In a similar study, Fitzjohn et al. (2001) tested a group of APPsw mutant mice and 
determined that LTP induction is not impaired with age. In the study, the authors found 
that in vitro CA1 synaptic transmission is, in fact, impaired in 12 month-old APPsw 
mice. Despite this impairment, however, in vitro LTP induction was found to be normal 
in the CA1 region of 12 and 18 month-old Tg+ mice using paired-pulse stimuli. Similar 
results were obtained when examining the induction of LTP in the dentate gyrus of 18 
month-old Tg+ mice. These findings seemingly contradict the results obtained by 
Chapman et al. (1999). Fitzjohn et al. (2001) suggests that these disparate conclusions 
could be explained by variations in basal synaptic transmission, possibly due to the use of 
kynurenate, a fixative that has been shown to mask deficits in synaptic transmission. 
A study by King and Arendash (2002a) sought to settle the disparities among the 
behavioral literature involving Tg2576 mice by documenting the impairments of Tg+ and 
Tg- mice in a full behavioral test battery at 4 distinct time points. Four groups of Tg2576 
and Tg- control mice were put through a six week battery of cognitive and sensorimotor 
tasks starting at 3, 9, 14, and 19 months of age, respectively. The authors found that Tg+ 
mice were more active in the open-field task at 3 months of age than their age-matched 
controls. While Tg2576 mice were not more active in the Y-maze for any given time 
point, the Tg+ mice did demonstrate a greater number of arm entries, overall, than non-
transgenic mice. These two measures indicate that Tg2576 are more active and may show 
less habituation to their environment. To assess sensorimotor performance, the Tg2576 
mice were observed in the balance beam and string agility tasks. Data collected for the 
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Tg2576 mice indicate that these mice are unable to remain on the beam for as long as Tg- 
mice at 3, 14, and 19 months of age. In general, a progressive decline in beam 
performance was evident for both Tg+ and Tg- mice with increasing age. Similarly, 
Tg2576 mice demonstrated inferior performance in the string agility task at 14 and 19 
months when compared to Tg-. Likewise, string agility declined with age in both Tg+ 
and Tg- mice. These measures indicate that Tg2576 mice, in particular at older ages, are 
far less agile and have less strength/agility than their Tg- counterparts. To elucidate any 
cognitive impairment in Tg2576 mice, several tasks were used. The Y-maze, in addition 
to indicating overall activity, can serve as a cognitive measure when percent alternation is 
analyzed. When compared to age-matched controls, Tg2576 mice showed a lower 
percent alternation (impaired performance) at 3 and 19 months of age, as well as overall. 
Other cognitive tasks, includ ing circular platform, Morris water maze acquisition, and 
Morris water maze retention, failed to demonstrate that the Tg+ mice were in any way 
impaired, overall or at any specific age. The Tg2576 mice were, however, impaired 
“overall” in the platform recognition task, as well as at 9, 14, and 19 months of age 
compared to Tg-. Both groups of mice displayed a decline in performance with advancing 
age. In the passive avoidance task, Tg2576 mice demonstrated a delayed latency to enter 
the dark chamber in pre-shock testing at 14 months, perhaps indicating their lack of 
exploratory behavior compared to Tg-. Surprisingly, Tg+ mice also displayed a greater 
latency to enter the dark chamber during post-shock testing at 9 and 14 months of age, 
perhaps due to greater fear/anxiety compared to Tg-. There was no transgenic effect, 
however, in the active avoidance task. Finally, Tg2576 mice experienced a significantly 
lower survivorship through 19 months than Tg-. Overall, it appears that, while Tg2576 
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mice demonstrate significant sensorimotor deficits, they experience very little cognitive 
impairment through 19 months of age. The nearly significant impairment at 19 months of 
age for the Morris water maze acquisition indicates that cognitive impairment might 
begin to occur beyond this time point. Another factor to consider is that the mice used in 
this study were of the C57BL/6 strain, which possess a particularly high level of 
intelligence, possible masking any transgene- induced impairments.  
In a companion study to the one just described, Arendash and King (2002) sought to 
determine what correlations exist between behavior performance measures in each of 
their tasks for the Tg2576 mice carrying the APPsw mutation and non-Tg+ mice. 
Determining the relationships between performances in different tasks could help us 
identify the common features inherent in these tasks. In addition, understanding which 
behavioral tests are correlated with one another could help us better assess the efficacy of 
therapeutics and treatments against AD in transgenic mice. When the performances of all 
169 mice were analyzed together, the authors found several correlations between 
behavioral tasks. First, it was discovered that open-field activity and the number of Y-
maze entries were highly correlated, underscoring the fact that both of these tasks assess 
overall activity/exploratory behavior. In addition, balance beam performance and string 
agility were also highly correlated, demonstrating the importance of balance and dexterity 
in each of these tasks. All four of these tasks can be classified as sensorimotor measures. 
When the authors looked at “intra-task” cognitive behavioral measures, they found that 
performance in the water maze acquisition trials was highly correlated with memory 
retention in the probe trial. Secondly, the number of errors made in the circular platform 
task, where the mice are asked to locate a single escape hole among 16 that will lead 
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them away from aversive stimuli, was found to be related to the overall escape latency. In 
addition, a number of “inter-task” correlations were found between measures in various 
cognitive tasks. For example, percent alternation in the Y-maze was found to be 
negatively correlated with circular platform errors and latency, indicating that those 
animals with better alternation ability in the Y-maze were quicker to locate the escape 
hole in the circular platform. Platform recognition escape latency, not surprisingly, was 
correlated with Morris Water Maze latency and circular platform latency, suggesting that 
each of these tasks requires similar cognitive traits. Performance in platform recognition 
was also determined to be inversely related to Y-maze alternation, indicating that the Y-
maze is also cognitive in nature. Finally, there were several correlations discovered 
between sensorimotor tasks and cognitive tasks. For example, open field activity and Y-
maze entries were found to be inversely related to circular platform latency, indicating 
that those animals that displayed higher activity in the open field and Y-maze were 
quicker at escaping from the circular platform. In addition, balance beam performance 
was determined to be inversely related to circular platform latency, demonstrating that 
the circular platform task may have certain sensorimotor components to it. Platform 
recognition latency, likewise, was found to have a negative correlation with balance beam 
performance and string agility, suggesting that the platform recognition may also contain 
some sensorimotor aspects. The implication of this data analysis is that performance in 
one behavioral task can be highly predictive of performance in another task. What’s 
more, these predictive correlations can be influenced by genetic background and age, as 
many behavioral tasks were only correlated with one another when mice were divided 
into groups of similar age and/or transgenicity. These results will go a long way towards 
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better understanding how behavioral measures are related and how they can be classified 
based on the skills they test. 
In another study, King and Arendash (2002b) attempted to correlate synaptophysin 
staining in the cortex and hippocampus of Tg2576 mice bearing the APPsw mutation 
with behavioral impairments. In the study, the authors used a specific antibody to stain 
for synaptophysin, a 38-kDa membrane glycoprotein that is localized to neuronal 
synaptic vesicles. Previous reports involving various transgenic strains of mice have been 
inconclusive concerning the precise relationship between synaptophysin staining,  Ab  
plaque formation, and aging. The current belief is that increased amyloid levels/plaque 
formation and the development of dystrophic neurites leads to a maintained area of 
synaptophysin staining. In the present study, King and Arendash (2002) found that Tg+ 
mice retain their high levels of synaptophyin staining through time, presumably signaling 
the formation of plaques, while Tg- mice begin to show a decline in staining as they get 
older. Consequently, by the age of 19 months, the Tg2576 mice show a significantly 
greater amount of synaptophysin staining than their Tg- counterparts, particularly in the 
deep and outer layers of the neocortex as well as dentate gyrus, outer molecular layer and 
polymorphic layer of the dentate gyrus in the hippocampus. This difference in staining 
between the two genotypes could not be explained by tissue atrophy. For behavioral 
analysis, the study employed 43 Tg2576 mice and Tg- controls divided into four age 
groups: 3, 9, 14, and 19 months. The authors found that, for all animals combined, those 
with greatest “cortical” synaptophysin staining demonstrated a heightened level of 
activity, as determined through the open field activity and Y-maze entry tasks. These 
animals were also observed to have difficulty in locating and swimming towards a visible 
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platform in the water maze. Animals that possessed increased “hippocampal” 
synaptophysin staining were found to have impaired performance in the balance beam 
task as well as deficits in spatial acquisition and retention in the Morris Water Maze task. 
When the 19 month-old animals were analyzed separately, high levels of cortical 
synaptophysin staining correlated with increased open-field activity only. Synaptophysin 
staining in the hippocampus of the 19 month-old mice correlated with impaired 
performance in the balance beam, water maze, and platform recognition tasks. In 
addition, the study found that, among 19 month-old animals, impaired performance in 
water maze acquisition correlated with decreased hippocampal thickness and several 
thinner hippocampal strata. These findings highlight the important interactions between 
AD pathology and behavior in transgenic mice. The results of this study are consistent 
with the hypothesis that maintained SYN-IR in brains of Tg2576 mice is associated with 
impaired synaptic function and, consequently, cognitive deficits. 
 In summary, the behavioral findings described here indicate that APP 
overexpression, and/or the process of Ab  deposition caused by the “Swedish” mutation to 
the APP gene, induces deficits in cognitive and sensorimotor function in transgenic mice. 
While the time course and extent of these deficits is still a point of contention, the current 
evidence points to a direct link between an increase in the amount of insoluble Ab  
oligomers/amyloid plaques and the onset of AD-like behavioral abnormalities. The 
existence of this link between pathology and behavior validates the APPsw transgenic 
line as a valuable model for testing potential therapeutics against AD. 
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Other Transgenic Models of Ab  Overproduction 
 Besides the APPsw mouse, there are other AD transgenic mouse models that 
demonstrate an overproduction of Ab . Among these models is the APPsw/PS-1 mouse, 
often called the PSAPP model. This model possesses two mutations that enhance Ab  
production—the “Swedish” mutation, which increases b-secretase activity, and the 
A246E PS-1 mutation, which increases g cleavage of APP. When these two mutations are 
combined, the result is a significant enhancement in the amount of Ab  generated in 
affected neurons, as well as an earlier onset of AD-like pathology. Takeuchi et al. (2000) 
found that PSAPP mice begin to display Ab  deposits in the neocortex, cingulate cortex, 
and hippocampus as early as 3 months of age. These deposits were observed to increase 
in size and density, encompassing the majority of the neuropil by 12 months of age. By 
comparison, APPsw mice in this study did not form any plaques until 6 months of age, 
becoming numerous only after 12 months. On average, PSAPP mice were found to 
contain between 19 and 73 times more Ab  deposits than comparably aged APPsw mice. 
Not surprisingly, PSAPP mice are found to demonstrate behavioral impairments as early 
as 5 months of age. Arendash et al. (2001) discovered that PSAPP mice are more active 
in Y-maze as early as 5 months of age. PSAPP mice are also impaired in the balance 
beam task beginning at 5 months of age as well as the string agility task beginning at 15 
months of age. PSAPP mice also demonstrate progressive impairments in Morris water 
maze acquisition and radial-arm water maze working memory between 5-7 and 15-17 
months of age. A follow-up study (Gordon et al., 2001), employing the same 15-17 
month-old subjects, found an inverse correlation between Ab  (especially in compact Ab  
deposits) in the frontal cortex/hippocampus and radial-arm water maze memory. Inverse 
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correlations were also found between compact Ab  loads in the frontal cortex and the 
delayed retention trial of RAWM testing. These findings indicate that PSAPP mice 
develop cognitive deficits in association with Ab  burdens.   
 Another transgenic mouse model that demonstrates an over expression of Ab is 
the APPV717F, or PDAPP model. The PDAPP model involves a point mutation on the 
APP protein, near the g-secretase cleavage site, that increases g-secretase activity. 
Behaviorally, an analysis of AD pathology described in a follow-up study (Dodart et al., 
2000) indicated that homozygous PDAPP mice begin to show Ab  deposits at 3-4 months 
of age, while only half of all heterozygotes develop plaques at this age. Early plaques 
were limited to the CA1 region of the hippocampus, medial cingulate cortex, and corpus 
callosum. By 6-7 months of age, Tg+ mice start to develop plaques in the parietal and 
perirhinal cortices. Finally, at 12 months of age, PDAPP mice demonstrate Ab  plaques in 
the frontoparietal and temporal cortices, with homozygous Tg+ mice averaging 3 to 4 
times more Ab  that age-matched heterozygous mice. Behaviorally, Dodart et al. (1999) 
examined a set of PDAPP mice and determined that Tg+ mice begin to show 
impairments in Radial-Arm water maze as early as 3 months of age, with homozygous 
mutants demonstrating a more profound level of impairment at an early age. These 
homozygous PDAPP mice also possess impairments in object recognition by 6 months of 
age, while heterozygotes remain unimpaired through 9 months of age. All PDAPP mice 
were shown to display greater locomotor activity from an early age. As an aside, the 
authors noted that most of the PDAPP mice examined in this study suffered from 
hippocampal atrophy and callosal agenesis from early adulthood onward---these two 
conditions may further impair the cognitive performance of PDAPP transgenic mice.  
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Tau Transgenic Models 
 As discussed in the introduction, the second major hallmark of AD is the 
formation of intraneuronal neurofibrillary tangles (NFT’s). NFT’s are composed of the 
microtubule-associated protein tau and their formation has been implicated in 
neurodegenerative disorders such as progressive supranuclear palsy (PSP), corticobasal 
ganglionic degeneration (CBD), and frontotemporal lobe dementia of the Parkinson’s 
type (FTDP) (Kwon, 2002). Six unique isoforms of the tau protein exist in the adult 
human brain, depending on how the tau mRNA is spliced from its gene, which is located 
on human chromosome 17. These isoforms can be identified based on the presence or 
absence of 29 or 58-amino acid inserts in the amino-terminal half of the tau protein and a 
31-amino acid repeat region located in the carboxy-terminal half. Isoforms that contain 
the 31-amino acid repeat are known as 4-repeat tau. Those isoforms that lack the 31-
amino acid are identified as 3-repeat tau (Kwon, 2002). NFT’s form when tau becomes 
hyperphosphorylated and dissociates from the microtubule to form paired helices that 
disrupt axonal conduc tion and, ultimately, results in the death of the neuron (Selkoe, 
2001). At present time, there are three known mutations to the tau protein that result in 
the production of NFT’s in transgenic mice: P301L, R406W, and V337M. The P301L 
mutation only affects 4-repeat tau isoforms, while R406W and V337M affect all tau 
isoforms. Each of these mutations involves changes to the microtubule binding repeat 
region of the tau protein, which is thought to result in the partial loss of function of tau 
and a reduced level of tau binding to the microtubules. Consequently, these mutations 
markedly increase the tendency of tau filaments to aggregate, leading to the formation of 
NFT’s (Kwon, 2002).  
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Although not many studies have been performed dealing with mice transgenic for 
the P301L mutation to tau, two important studies describe the pathology and motor 
behavior associated with this mutation. In the first study, Lewis et al. (2000) observed a 
group of JNPL3 mice carrying the P301L mutation. As early as 6.5 months of age, the 
authors found that mutant P301L mice possessed neurofibrillary tangles in the 
diencephalon, brain stem, cerebellar nuclei, and spinal cord. The authors also found “pre-
tangles” and tau-positive processes in neurons of the cortex, hippocampus, and basal 
ganglia. In addition, gliosis was observed in the spinal cord, brain stem, diencephalon, 
and basal telencephalon of Tg+ mice, with up to a 48% loss of motor neurons in the 
spinal cord. At 4.5 months of age, homozygous P301L mutants displayed a lack of escape 
extension during tail elevation, spontaneous back paw clenching while standing, a 
delayed righting response, and could only hold onto a string briefly before falling. 
Hemizygous mice began experiencing these same behaviors at 6.5 months of age. In 
addition, Tg+ mice demonstrated a reduction in grooming, weight loss, fewer 
vocalizations, and increased eye irritation. These animals began to demonstrate hindlimb 
paralysis by 8-10 months of age, with morbidity within 3-4 weeks thereafter. By contrast, 
JN4 and JN25 mice, which do not express the P301L mutation at the same level as the 
JNPL3 strain, failed to show any such impairment. Tg- controls, likewise, displayed 
normal behavior. These findings, therefore, seem to correlate the formation of NFTs in 
the brain and spinal cord with neuronal loss and sensorimotor abnormalities. 
 A study of mice bearing the V337M mutation to tau, a slightly less potent 
mutation than P301L, showed that these animals also demonstrate behavioral 
abnormalities (Tanemura et al., 2002). V337M mice at 11 months of age were found to 
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have increased activity in the plus maze, spending most of their time in the open arms, as 
well as increased activity in the open field. The V337M did not show any impairment in 
the Morris Water Maze. Pathologically, these mice develop NFT’s by 10-14 months 
within the hippocampus, as evidenced by irregularly shaped neurons, an accumulation of 
RNA in the neuronal cytoplasm, and a lack of normal a-tubulin (indicating a loss of 
microtubules). In addition, an ana lysis of neural activity in the hippocampi of V337M 
mice, following an applied stimulus at the Schaeffer collaterals, indicated that Tg+ mice 
generate a weaker depolarization response in the stratum pyramidale and stratum 
radiatum. Because the P301L mutation leads to an early neuronal death in transgenic 
mice, it is difficult to observe its pathology. Therefore, these pathological observations of 
V337M mice are of special interest. The V337M mutation, unlike the P301L mutation, 
does not lead to neuronal cell death in mice. Instead, V337M mutant mice develop 
degenerative neurons, featuring atrophy of the nucleus and cytoplasm. 
Tatebayashi et al. (2002) described the pathological changes and associative 
memory deficits in Tg+ mice with another mutation to the tau protein, R406W. Like the 
V337M model presented by Tanemura et al. (2002), this R406W mutation, under the 
control of the CaMK-II promotor, is only expressed in areas of the forebrain, specifically 
the hippocampus, neocortex, olfactory bulbs, striatum, and thalamus. According to the 
authors, R406W mice begin to show NFT formation in these forebrain areas as early as 
18 months of age. Tg- mice, accordingly, fail to demonstrate any abnormal tau pathology 
at this same time point. The authors also report the presence of abnormally shaped 
neurons in parts of the hippocampus, taking on a flame-like shape. These abnormal 
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neurons were found to lack microtubules, but contained thin tau filaments, an observation 
made previously by Lewis et al. (2000) in their study involving P301L mice.  
To assess the physical impairments caused by expression of the R406W tau 
mutation, the authors observed a group of 16-23 month-old Tg+ mice and their Tg- 
littermates (at an age when Tg+ mice begin to show NFT formation) through a variety of 
sensorimotor and learning tasks. The authors reported no significant transgenic effect in 
any of the sensorimotor tasks; including acoustic startle response, accelerating rotarod, 
and pole tests. The study did conclude, however, that Tg+ mice are deficient in certain 
types of associative memory. The authors discovered that R406W mice are impaired in 
contextual fear conditioning when tested 15 days after training, compared to Tg- controls. 
Tg+ mice also showed deficiencies in cued fear conditioning when tested 48 hours after 
receiving training. Tg- mice demonstrated a normal cued conditioning response 
(Tatebayashi et al., 2002).  
A second study conducted by Lewis et al. (2001) presented the pathology associated 
with a group of transgenic mice bearing both the P301L tau mutation and the APPsw 
mutation. These mice were generated by crossing a line of Tg2576 mice expressing the 
APPsw mutation with a group of JNPL3 mice expressing the P301L tau mutation. The 
authors were very curious to see if the presence of brain Ab  would have an effect on the 
formation of NFTs, thus more closely simulating the conditions present in human AD 
pathology. Lewis et al. (2001) found that the APPsw/P301L (TAPP) mice and APPsw 
singly transgenic mice each possessed a similar number of Ab  plaques in the amygdala, 
olfactory cortex, cingulated gyrus, entorhinal cortex, and hippocampus starting at 6 
months of age. The P301L mutation, therefore, did not result in enhanced Ab  deposition. 
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The TAPP mice, like the P301L singly transgenic mice, began to display NFT formation 
in the spinal cord and pons as early as 3 months of age. The NFTs from the TAPP mice 
and the P301L mice were identified as being morphologically similar to one another. 
Interestingly, the authors found that older female TAPP mice, between the ages of 9-11 
months, displayed up to 7 times more NFTs than the age-matched P301L female cohort, 
primarily in olfactory cortex, entorhinal cortex, and amygdala. In addition, these female 
TAPP mice displayed some NFTs in the subiculum, hippocampus, and the isocortex, 
areas of the brain, where NFTs are rarely found in JNPL3 mice. In subcortical areas of 
the brain, however, there was little difference in the concentration of NFTs between 
female TAPP mice and P301L mice. The authors did note, however, that areas of the 
brain with high concentrations of amyloid plaques failed to show a concomitant increase 
in tangles. These results suggest that a high Ab  environment, and not the formation of Ab  
plaques, is directly responsible for the increase in the number of NFTs. Like the P301L 
mice discussed earlier, these TAPP mice displayed similar motor disturbances and hind 
limb paralysis with the same age of onset. The Tg2576 mice did not show any of these 
impairments. In general, it appears that an interaction between Ab  (or possibly APP) and 
tau is occurring in the brains of TAPP mice that is leading to an increased number of 
NFTs and a similar level of sensorimotor and behavioral impairments as in tau mice.  
 Götz et al. (2001) performed a related study to better understand the relationship 
between Ab  and tau. In this study, the authors injected synthetic Ab42 fibrils into the 
sensory cortex and hippocampus of 5-6 month-old P301L mutant mice. A second group 
of P301L mutant mice were injected with the reversed sequence of Ab42 to serve as a 
control. Pathological comparisons between the test and control groups indicated that the 
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mice injected with Ab42 had up to five times more NFTs in the amygdala than the 
injection control P301L mice. A time-course analysis of the injected P301L mice 
revealed that NFTs begin to form approximately 18 days following the injection of Ab  
fibrils and continue to increase in number unt il 60 days post- injection. Interestingly, the 
authors noted that the formation of NFTs occurs remotely from the site of Ab  injection. 
The rationale for this observation is that NFTs form in the cell bodies of neurons that 
terminate at the Ab  deposition site. This theory is confirmed by the fact that the P301L 
mice that received the Ab  injection demonstrated an increased amount of NFTs in the 
amygdala, where most of the neurons whose axons terminate at the site of injection have 
their cell bodies. Further, it appears that the induction of NFT formation by Ab  occurs 
through the hyperphosphorylation of tau. Only the Ab-injected mice showed any 
reactivity to two antibodies that bind specifically to tau phospho-epitopes S422 and 
S212/T214, respectively. This finding seems to indicate that Ab  induces a mechanism 
that leads to the phosphorytion of tau at these two residues and the formation of abnormal 
NFTs.  
 According to the conclusions of Götz et al. (2001) and Lewis et al. (2001), it 
appears that the combination of Ab42 and mutant tau protein leads to an increased number 
of neurofibrillary tangles in addition to the amyloid plaques present with the APPsw 
mutation alone. Currently, the only mouse model that contains these two pathological 
hallmarks of Alzheimer ’s disease is the TAPP mouse, which possesses both the APPsw 
mutation as well as the P301L tau mutation. The creation of this mouse model is critical, 
as its pathology seems to more closely approximate the characteristics of human AD than 
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any other mouse model currently available. As such, the TAPP mouse model represents a 
great potential for testing possible treatments and enhanced therapeutics against AD.  
 
Retinal Degeneration 
 In the literature, it has often been reported that mice and other rodents are 
sometimes known to suffer from a type of retinal degeneration that leads to near complete 
blindness in affected individuals. This retinal degeneration is caused by an autosomal 
recessive defect in the b-subunit of the rod-specific cGMP-PDE gene. The defect blocks 
the phototransduction cascade, thus causing increased cGMP levels and ensuing 
induction of Ca2+ channels to remain open (Ogilvie and Speck, 2002). This mutation, 
often abbreviated as the rd mutation, leads to the rapid degeneration of rods within three 
weeks after birth, eventually leading to the loss of cones, as well. While the mechanism 
responsible for this retinal degeneration is not fully understood, it is thought that the 
process involves a type of apoptotic cell death. (Ogilvie and Speck, 2002). Recently, 
several studies have attempted to determine the extent to which retinal degeneration 
might result in behavioral impairment. Spencer et al. (1995) performed such a study on a 
group of aged, Sprague-Dawley rats with varying degrees of spontaneous retinal 
degeneration. The authors found that those rats with the most severe retinal degeneration 
performed significantly worse in the Morris water maze than those rats with less severe 
retinal degeneration. Further, when the rats were re-tested in the Morris maze with the 
platform placed in a new quadrant, the mice with more severe degeneration were unable 
to learn the location of the new escape. Rats with less severe retinal damage were able to 
learn the new location of the escape platform relatively quickly. In addition, severely 
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degenerate rats spent far less time in the goal quadrant during a probe trial than less 
degenerate rats. Likewise, Cook et al. (2001) determined that mouse strains carrying the 
rd1 retinal degeneration gene display far less anxiety than rd- mouse strains when placed 
in an elevated zero maze, preferring to spend more time in the open arms. In contrast, a 
study performed by Fuller et al., (1973) indicates that rd/rd mice placed in a spatial water 
T-maze are not significantly impaired in their ability to locate an escape ladder over a 
period of 25 days of testing. The authors concede that visual cues play a negligible role in 
this particular water maze, perhaps explaining why rd/rd mice fail to demonstrate an 
impairment. Thus, it appears that retinal degeneration can have a significant effect on the 
performance of mice and other rodents in behavioral tasks that require visual acuity. 
Consequently, special attention must be placed on determining whether mice that are to 
be behaviorally tested are homozygous for this mutation.  
 
 While the literature is fairly complete with regards to the behavior and pathology 
of the APPsw mouse model, little is known about the behavioral impairments associated 
with the P301L tau mutation. Even less is known about the pathology and behavioral 
impairments associated with the Tau+APP model of AD. Given the importance of 
creating the most ideal model with which to test potential treatments and therapeutics 
against AD, it would seem vital to have a better understanding of how the behavioral 
impairments of P301L or APPsw+P301L mice compare to that of the APPsw mouse. The 
specific aims of my research, therefore, will be the following: 
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· Perform a full battery of sensorimotor and cognitive tests on a group of APPsw, 
P301L, APPsw+P301L, and Tg- control mice, in order to compare the extent of 
behavioral impairments associated with each of these three transgenic lines. 
· Determine the effect of the retinal degeneration gene on behavioral performance 
across all four genotypes. 
· Elucidate any correlations between the number of tau positive neurons in the 
brains of P301L mice and the extent of their behavioral impairment. 
· Test the ability of Discriminant Function Analysis (DFA) to distinguish the four 
genotypes based on behavioral performance in test battery.  
· Use Factor Analysis (FA) to group behavioral measures that share common 
factors. 
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Methods 
Animals 
A total of 32 mice in four groups were behaviorally evaluated in this study: 7 
mice carrying the “Swedish” APP double point mutations Lys670®Asn and Met671®Leu 
(APPsw), 10 mice possessing the Pro301®Leu tau mutation (P301L), 4 mice expressing 
both the P301L and APPsw mutations, and 11 non-transgenic control mice. The mice 
were selected from the progeny of a cross between C57B6/SJL x SW/B6D2F mice 
bearing the APPsw mutation and C57BL/DBA2 mice carrying the P301L mutation. All 
subjects employed in the study were female. Several months prior to initiation of 
behavioral testing, mice were individually housed in ALAC approved cages with access 
to rodent chow and water under a 12-hour light/dark cycle. Animal care and use was in 
accordance with the Guide and Use of Laboratory Animals, National Research Council, 
1996, in a program and facilities fully accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care, International, under protocols approved by the 
University of South Florida Institutional Animal Care and Use Committee (No. 1609, 
David Morgan, PhD., Principal Investigator). Behavioral testing was performed only 
during the day portion of the circadian cycle. 
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General Protocol 
 At 5 months of age, animals were started in a 6-week behavioral test battery 
(Arendash et al., 2001) to evaluate their sensorimotor abilities, anxiety levels, and 
cognitive performance. A few noted tasks were repeated after the completion of the initial 
test battery at the ages indicated. The following tasks were evaluated in the order 
indicated and at, or beginning at, the age indicated: 
Open field activity           5M   
Balance beam               5M,  6.5M,  8.5M  
String agility               5M,  6.5M  
Y-maze spontaneous alternation 5M,  8.5M  
Elevated plus-maze (anxiety)  5M  
17-measure neurologic screen 5.5M  
Morris maze (acq. & retent.)  5.5M  
Circular platform escape  6M  
Platform recognition              6M  
Radial-arm water maze            6.5M   
Visual cliff (visual acuity)   7M 
 
 Upon completion of behavioral testing, all animals were euthanized at 9 months 
of age, wherein they were transcardially perfused with 25mL 0.9% saline according to 
the procedure outlined in Gordon et al., (2002). Brains of the P301L mice were promptly 
removed and the left hemispheres were immersion-fixed in freshly depolymerized 4% 
paraformaldehyde (pH 7.4) for 24 hours. The hemispheres were then cryoprotected using 
a series of sucrose solutions and later frozen and cut through the horizontal plane into 
25mm sections using a sliding microtome and stored at 4oC in Dulbecco’s phosphate-
buffered saline. Tau+ neurons were stained using an anti-phosphorylated tau primary 
antibody, incubated at 4oC for 18 hrs. A biotinylated secondary antibody was added for 
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120 min., followed by avidin-biotin-peroxidase complex, using the Vectastain Elite kit, 
for 5 minutes. The Oncor V150 color image analysis system was used to quantify the 
number of stained Tau+ neurons in the hippocampus, cortex, amygdala, brain stem, and 
whole brains of the P301L mice. For each brain region, 4 to 16 horizontal sections were 
stained and analyzed, spaced between 2000 and 3600mm ventral to bregma. The 
measurement area for each region was a rectangular video field of 850,000mm2. For each 
region, the measurement area was carefully positioned such that the sections from each 
mouse could be matched as closely as possible.  
 Genotyping for the rd gene, as well as the APP and Tau transgenes, was 
performed using PCR of a DNA sample extracted from the tails of all experimental 
subjects (Gordon, personal communication). 
 
Specific Behavioral Testing Procedures 
Open Field. To assess general levels of activity and exploratory behavior, each mouse 
was placed in the center of a square (81 x 81cm) open black box with 28.5 cm walls and 
lines painted on the floor to demarcate 16 squares (each 20 x 20cm). Each mouse was 
allowed to roam freely for five minutes inside the box. The total number of lines crossed 
during the 5-minute period was recorded.  
 
Balance Beam. In order to evaluate balance and general motor function, each mouse was 
tested on a 1.1-cm wide beam, suspended 45.7 cm above a padded surface and supported 
by two columns, 50.8 cm apart. At either end of the beam was an attached 14 x 10.2 cm 
escape platform. Each mouse was placed on the center of the beam in a perpendicular 
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orientation and released for a period of up to 60 seconds. The total time spent by the 
animal on the beam before falling (not to exceed 60 seconds) was recorded for each trial. 
A total of three trials were performed in succession. If the animal was successful in 
escaping onto the platform, a score of 60 seconds was recorded. The average score for the 
three trials was calculated and recorded. This task, first done at 5 months, was repeated at 
6.5 months and 8.5 months of age.  
 
String Agility. To assess forepaw grip capacity and agility, animals were placed at the 
center point of a tautly-suspended cotton string for a period of up to 60 seconds. The 
string was suspended by the same two columns used in the balance beam task, 33cm 
above a padded surface. Each animal was allowed to grasp the string with only its 
forepaws, then released for the 60 second trial. A rating system was used to quantify each 
animal’s string agility: “0” if the animal is unable to hang onto the string for any length 
of time, “1” if the animal hangs by its forepaws for 60 seconds, “2” if the animal makes 
an attempt to pull itself up onto the string, “3” if the mouse places both forepaws and at 
least one hindpaw on the string, “4” if the animal places all four paws and tail around the 
string with some lateral movement, and “5” if the animal escapes to the support column. 
The string agility score for each animal was recorded. This task was initially performed at 
5 months and repeated at 6.5 months.  
 
Y-maze . As a measure of general activity and basic mnemonic function, mice were tested 
in a black Y-maze with three arms measuring 21 x 4 cm and surrounded by 40-cm walls. 
Each mouse was placed into one of the three arms facing the middle area, and allowed to 
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roam the maze for five minutes. The total number of arm entries and sequence of arm 
entries were both observed and recorded for each mouse. Alternation, expressed in the 
form of a percentage, was defined as the ratio of arm entries differing from the previous 
two entries divided by the total number of entries. Thus, if an animal made the following 
sequence of arm entries (3,2,1,2,3,2,1,3), the total number of alternation opportunities 
would be six (total entries minus two) and the percent alternation would be 67%. Y-maze 
performance was initially evaluated at 5 months, and then repeated at 8.5 months of age.  
 
Elevated Plus Maze. To assess anxiety/emotionality, all animals were evaluated using a 
plus-shaped maze elevated 82 cm above the floor. The maze consists of four arms, each 
30 x 5 cm, including two opposite “closed” arms surrounded by dark walls and two 
opposite “open” arms that are exposed without any walls. In the center of the maze is a 5 
x 5cm common area. For the single trial given, each mouse was placed at the center of 
the maze facing a closed arm, and allowed to freely explore the maze for a period of five 
minutes. During this trial, the amount of time (in seconds) spent in the open arms was 
observed and recorded, as well as the number of open arm choices and closed arm 
choices.  
 
17-Measure Neurological Screen. A comprehensive neurological screen, largely derived 
from Irwin, (1966), was employed to further determine if any of the mice exhibited 
sensorimotor impairments related to their genotype. All of the mice were initially 
observed for transfer arousal, on a scale from 0 to 8 (with 0 = no activity) when moved 
out of their home cage and into a novel environment. Each mouse was then assessed for 
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the presence of an ataxic or hypotonic gait, as well as pelvic elevation, and tail elevation 
on a subjective 0 to 8 scale, with 0 being normal. Each mouse was also presented with 
two types of stimuli to assess their level of response. A cotton Q-tip was used to gently 
rub the animal’s eye, in order to assess the mouse’s eye blink response, or corneal 
opacity. The Q-tip was also used to gently poke the animal on its nose to quantify the 
animal’s withdrawal reflex, as well as its tendency to approach the static Q-tip. A scale of 
0 to 8 (8 = greatest response) was used for all three of these measures. The animal was 
also presented with a loud “cricket” noise. A similar scale was used to quantify the extent 
of the mouse’s response. In addition, each animal’s level of anxiety and activity in 
response to being touched was assessed on a 0 to 8 scale. A wire mesh grid was 
employed to test the mouse’s grip strength us ing its front paws. The mesh was also used 
as a test of vision by evaluating at what point the mouse will reach out for the grid when 
suspended by its tail and lowered to a grid just out of reach. Each mouse’s vision and 
anxiety were also tested by assessing whether it would hesitate at the edge of a visual 
cliff. Vision and anxiety were also evaluated in the elevated platform task, where the 
animal is placed in the center of an elevated circular platform (21 cm in diameter) for a 
period of 60 seconds. The latency to first head poke over the side, as well as the number 
of times the mouse poked its head over the side of the platform was observed and 
recorded. The mouse’s righting reflex was assessed by placing the animal in an empty 
cage and gently shaking it while observing if the mouse is able to remain upright. This 
observation was recorded as a simple yes or no answer. Finally, the toe pinch and tail 
pinch tasks were administered to test the animal’s reflexes to painful stimuli.  
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Morris Water Maze. To measure reference learning (acquisition) and memory 
(retention), mice were placed into 100-cm circular pool filled with water at 22-27oC. The 
pool was divided into four equal-sized quadrants with the use of two black lines drawn 
along the bottom of the pool. The pool was surrounded by various visual cues, including 
a halogen lamp, beach ball, colored wall poster, camera stand, as well as the 
experimenter, which helped the mice to orient their location in the pool. A clear, 9-cm 
platform was placed in the middle of quadrant II (QII), such that the surface of the 
platform was exactly 1.5 cm below the water surface and visually indiscernible to the 
mice. Reference learning (acquisition) occurred over a nine-day period with four 
successive trials per day. On each trial, the animal was started from a different quadrant, 
with the same quadrant start pattern taking place on each day of testing. The latency to 
find the platform (up to 60 seconds) for each trial was recorded and a daily average 
recorded for each animal. After locating the platform, the mouse was allowed to remain 
on the platform for 30 seconds. If the animal failed to discover the location of the 
platform in 60 seconds, it was guided to the platform and then allowed to stay for 30 
seconds. A latency of 60 seconds would be entered into the record for such an 
occurrence. On days 4, 7, and 10 (prior to acquisition testing, for days 4 and 7), each 
mouse was administered a memory retention (probe) trial by allowing the animal to swim 
in the pool for 60 seconds after the platform had been removed. Only one trial was 
performed and the mouse was allowed to start swimming from a location just opposite to 
the former platform quadrant. Each mouse’s retention trial was recorded on videotape 
and the amount of time spent in each quadrant as well as average swim speed were later 
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calculated and recorded. Mice were always allowed to dry under heat lamps before being 
returned to their respective home cages. 
 
Circular Platform. As a test of spatial learning/memory, each animal was observed in an 
enclosed, 69-cm circular platform with 16 holes spaced 1.3 cm apart around the periphery 
of the platform. A black curtain decorated with visual cues enclosed the platform. To 
provide aversive stimuli that would motivate the test animals to escape the platform 
surface, two 150-watt flood lamps were hung 76 cm above the surface of the platform 
and a high-speed fan was mounted 15 cm above the platform surface Escape is only 
possible through one of the 16 holes, where a box filled with bedding is placed 
underneath the hole. The escape hole was changed for each animal, such that the same 
animal would experience the same escape location for each day of testing, but different 
mice would have different escape locations. Prior to actual testing, each mouse 
underwent several “shaping” trials, wherein they were guided from the center of the 
platform to their correct escape location. Following the shaping trials, animals were 
tested for 8 days, with one trial per day. On each day, mice were placed in the center of 
the platform, facing away from their respective escape hole, and allowed five minutes to 
freely explore the platform. The total number of errors, defined as the number of times 
the mouse poked its head through a non-escape hole, and the latency to find the escape 
hole (up to 300 seconds) were recorded for each mouse.  
 
Platform Recognition. To test for ability to recognize/locate a variably-placed visible 
platform, each mouse was tested in the same pool used for the Morris Water Maze task. 
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Instead of using a submerged, clear platform, however, the platform recognition task 
employed a 9-cm circular platform raised 0.8 cm above the surface of the water with a 
large 10 x 40 cm black and white ensign attached to the surface of the platform. The same 
visual cues used in Morris Water Maze were again used in this task. Unlike the Morris 
Water Maze task, however, all mice were started from the same location in the pool while 
the platform was moved to a different one of the four quadrants for each trial. Each 
mouse was tested for four days, with four trials per day. All four daily trials were 
averaged for statistical analysis. For each trial, mice were allowed to swim freely for 60 
seconds or until they located and ascended the platform. Upon reaching the platform, the 
mice were given a 30 second stay. Mice who failed to reach the platform in the allotted 
60 seconds were guided there and allowed to stay for 30 seconds. Following daily testing, 
mice were allowed to dry under heat lamps before being returned to their respective home 
cages.  
 
Radial-Arm Water Maze. For assessment of working memory, each mouse was tested 
in the same 100-cm inflatable pool used in the Morris maze and platform recognition 
tasks, but with an aluminum frame insert added. This created six swim arms (30.5 cm 
length x 19 cm width), radially distributed around the pool from a central circular swim 
area of 40 cm in diameter. The aluminum walls stood approximately 5 cm above the 
water surface. The same visual cues used in the Morris maze and platform recognition 
tasks were again employed in this task. Each mouse was assessed in four successive 
acquisition trials and one retention trial for each of the 12 days of testing. The last of the 
four consecutive acquisition trials (T4) and the retention trial (T5) are an index of 
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working memory.  On each testing day, the same clear, submerged platform used for the 
Morris water maze was placed at the end of one of the six swim arms. The platform 
location was changed to different arms for each of the 12 days of testing in a semi-
random pattern. The start arms for each of the four acquisition trials (T1-T4) and 
retention trial (T5) were selected in a semi-random sequence from the remaining five 
swim arms. For each acquisition trial, the mouse was placed at the end of the selected 
start arm, facing the center of the pool. Each trial lasted one minute in duration, during 
which the mouse was allowed to leave the start arm in search of the submerged escape 
platform. An error was defined as each time the mouse swam into a non-goal arm or any 
time the mouse swam into the goal arm without successfully locating the platform. 
Following each recorded error, the mouse was returned (across the surface of the water) 
to the appropriate start arm to continue the trial. Additionally, any animal that failed to 
make an arm choice within 20 seconds of leaving the start arm was pulled back to the 
appropriate start arm, assessed an error, and allowed to continue the trial. Each trial was 
continued until the mouse located the platform or for a maximum of 60 seconds. Any 
animal that failed to locate the platform in 60 seconds and made fewer than 3 choices was 
assigned 3 errors for the purpose of statistical analysis. Upon reaching the platform, the 
mouse was allowed to stay for 30 seconds before starting the next trial. If the mouse was 
unsuccessful in locating the platform in 60 seconds, it was guided to the platform and 
then allowed to stay for 30 seconds. For each of the four acquisition trials, the number of 
error choices made prior to escape as well as the latency to locate the hidden platform, 
were each recorded. Following the final acquisition trial (T4), the mouse were allowed to 
dry under a heat lamp and then returned to its respective home cage for a 30-minute delay 
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period. After 30 minutes, the mouse was returned to the pool for a single delayed 
retention trial (T5). The same procedures as in the acquisition trials were followed and 
the mouse was once again allowed to dry before being returned to its home cage.  
 
Statistical Analysis 
On the basis of genotypic analysis discussed earlier, the 32 test subjects were 
divided into groups based on their transgene genotype (NT, APPsw, tau, or TAPP) as 
well as their rd status (+/+, rd/+, or rd/rd). Table 1 indicates the number of test subjects in 
each of these categories. Since rd/+ mice fail to show retinal degeneration, they were 
grouped with +/+ mice for the purposes of statistical analysis. To determine the relative 
effects of the rd gene and transgenicity on performance in each of the previously 
described tasks, a two-way analysis of variance (ANOVA) was performed for each task, 
using the Statistica analytical software package, with rd status and transgenicity as the 
grouping variables. Following the ANOVA, post-hoc differences between groups (pair-
by-pair differences) were resolved using Fisher’s LSD test.  
For statistical analysis of 28 selected behavioral measures for rd status and 
genotypic effects, behavioral tasks were divided between those that were single day tasks 
and those that involved multiple days of testing. The single day tasks (e.g.: open field, 
balance beam, string agility, plus maze, Y-maze, and water maze retention) were 
analyzed using a simple two-way ANOVA with the grouping variables described above. 
The multi-day tasks (e.g.: Morris water maze, circular platform, platform recognition, and 
radial-arm water maze) were analyzed using a simple two-way ANOVA as well as a two-
way repeated measures ANOVA. Unless otherwise noted, all group differences were 
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deemed significant at p < 0.05. For each task, animals defined as non-performers were 
eliminated from further statistical analysis in that task. 
Table 2 indicates the relative effects of retinal degeneration and genotype, as well 
as the interaction between the two, on performance in each of the previously mentioned 
tasks. Based on recent findings describing the effects of retinal degeneration on 
behavioral performance (Spencer et al., 1995; Cook et al., 2001) as well as the statistical 
analyses described in Table 2 showing rd/rd status impairs cognitive performance in a 
number of tasks, it became necessary to remove all test subjects bearing the rd/rd 
genotype from this study. As indicated by Table 1, the removal of all test subjects bearing 
the rd/rd genotype left only one mouse carrying the TAPP double mutation. Since the 
performance of this single TAPP mouse was comparable to the performance of the APP 
group in all tasks except for circular platform and elevated plus maze, it was grouped 
with the APP subjects for all tasks except for circular platform and elevated plus maze. 
After the test subject pool was reduced in number following the removal of all 
mice carrying the rd/rd gene, the data was re-analyzed in order to compare the 
performance of NT (n=7), APPsw (n=4), and tau transgenics (n=7). Group differences 
were calculated as described above, using transgenicity as the only grouping variable, 
with the following differences. String agility was analyzed using the Kruskal-Wallis non-
parametric test and Mann-Whitney U-Test, instead of ANOVA. In addition to the 
measures previously discussed, all 19 sensorimotor battery tasks were analyzed using the 
Kruskal-Wallis test and Mann-Whitney U-Test, with the exception of visual cliff, head 
poke latency, and number of head pokes; these 3 measures were analyzed using ANOVA. 
Further, all single day tasks that were performed repeatedly (balance beam, Y-maze, and 
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water maze retention), were analyzed individually using ANOVA, then assessed with a 
repeated measures ANOVA to identify progressive changes between the performance of 
each group. In addition, an ANOVA was performed on the overall means for these tasks 
to assess overall performance across the time frame in question. For all multi- trial tasks 
(Morris water maze acquisition, circular platform, platform recognition, and RAWM), 
group differences on the last day of testing were analyzed using ANOVA. Finally, swim 
speed in the water maze retention task was determined using the Accuroute tracing 
program and group differences analyzed via ANOVA. ANOVA was also used to analyze 
quadrant preference within each group and percent time spent in quadrant 2 (the former 
goal quadrant) across all groups.  
In order to group behavioral measures by their common factors, all data was 
evaluated through factor analysis using the Systat statistical software package. Factor 
analysis works by considering all of the collected data, irrespective of transgenicity, and 
grouping those measures into factors, each of which is measuring a different component 
of behavior (i.e.: sensorimotor function, working memory, etc.). In this way, behavioral 
measures related to one another might be determined, as well as how performance in one 
task might be predictive of performance in another task. Two separate factor analyses 
were run, each using a different grouping of the measures evaluated for all 18 test 
subjects. The first analysis employed a comprehensive 39-measure dataset, while the 
second analysis employed a more selective 19-measure subset of the behavioral data (see 
Diagram 1). 
To determine whether the 3 genotypic groups (NT, APP, and Tau) could be 
distinguished from one another behaviorally, discriminant function analysis (DFA) was 
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Diagram 1: Measures Included in Multivariate 
                   Analyses
39-Measure 19-Measure 32-Measure 15-Measure
FA FA DFA DFA
OF
BB 1
BB 2
BB 3
BB Avg
STR 1
STR 2
STR Avg
YM-Alt 1
YM-Ent 1
YM-Alt 2
YM-Ent 2
YM-Alt Avg
YM-Ent Avg
EPC
EPO
EPT
WM Fin
WM Avg
WM RET 1
WM RET 2
WM RET 3
WM RET Avg
CPE Fin
CPE Avg
CPL Fin
CPL Avg
PR Fin
PR Avg
RAWM B4T1E
RAWM B4T4E
RAWM B4T5E
RAWM T4E
RAWM T5E
RAWM B4T1L
RAWM B4T4L
performed on both a 32 and 15-measure dataset (see Diagram 1), using the Systat 
analytical software package. Circular platform and elevated plus maze measures were not 
used in DFA analyses to avoid any conflicts from grouping the single TAPP mouse with 
the APP group of mice in these two tasks (wherein the TAPP mouse’s performance was 
appreciably different from that of 
the APP mice.) Two unique DFA 
analytical methods were 
employed in this study, direct 
entry method and stepwise-
forward method. The direct entry 
method utilized all behavioral 
measures in the discriminant 
function model.  In contrast, the 
stepwise-forward method selects 
measures iteratively for inclusion 
in the final discriminant function 
model based upon their variance 
contribution; only those measures 
that best discriminate between 
groups are included in the final 
model. 
Finally, correlation 
analysis was performed, using the 
 50
 
Systat analytical software package, to determine whether a relationship exists between the 
number of tau+ neurons in the brains of P301L mice and behavioral measures collected 
from the same animals. Five measures of tau pathology (number of tau+ neurons in the 
brainstem, cortex, hippocampus, amygdala, and whole brain) were used for this 
correlation analysis with the same 39 behavioral measures used for factor analysis (see 
Diagram 1)  
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Results 
Behavioral Effects of the rd Genotype 
 Table 1 shows the distribution of rd genotypes, by transgenic group, for all 32 
animals in the study. Significant percentages of animals in all four groups were 
determined to be homozygous recessive (rd/rd) for the retinal degeneration gene, with the 
remaining animals being heterozygous (unaffected carriers) or normal. To determine the 
effect of rd homozygosity and transgenicity on behavioral performance, behavioral 
measures from all 32 animals were analyzed for main effects of rd homozygosity and 
transgenicity, as well as for the interaction between the two. As summarized in Table 2, a 
main effect of rd homozygosity was evident in multiple behavioral measures from most 
cognitive-based tasks—particularly Morris water maze, platform recognition, and the 
RAWM tasks. These effects of rd homozygosity on cognition were always deleterious in 
impairing performance in tasks requiring good eyesight. By contrast, sensorimotor tasks 
(e.g.: open field activity, balance beam, and string agility) were not affected by rd 
homozygosity. Also unaffected were anxiety measures in the elevated plus maze and Y-
maze spontaneous alternation, a cognitive-based task not reliant on good eyesight.  
 Given the wide-spread deleterious effects of rd homozygosity on performance in 
multiple cognitive-based tasks/measures, data from all rd/rd mice (n=14) was eliminated 
from the remainder of this study so that transgenicity effects could be unequivocally 
evaluated. In addition, the one Tau+APP mouse that was not rd homozygous was 
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Table 1: Distribution of wild-type (+/+), heterozygous (+/rd), and homozygous (rd/rd)
              mice by Genotype
Genotype Total +/+ or +/rd rd/rd
Non-Transgenic 11 7 4
Tau 10 7 3
APP 7 3 4
Tau+APP 4 1 3
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Table 2: Effects of rd homozygocity and genotype on behavioral performance
              (P values indicated)
rd/rd Genotype
effect effect
Open Field 0.83 0.18 0.28
Balance Beam 1 0.41 <.01 0.94
Balance Beam 2 0.10 0.02 0.87
Balance Beam 3 0.14 0.01 0.52
String 1 0.65 0.98 0.41
String 2 0.91 0.78 0.47
Plus Maze (#CA) 0.77 0.73 0.50
Plus Maze (#OA) 0.51 0.34 0.04
Plus-Maze (time in OA) 0.30 0.29 <.01
Y-maze 1 (Entries) 0.02 0.05 0.07
Y-maze 2 (Entries) 0.19 0.54 0.89
Y-maze 1 (%-Alt) 0.27 0.13 0.22
Y-Maze 2 (%-Alt) 0.67 0.01 0.35
Morris Maze Avg. Acqusition <.01 0.28 0.24
Morris Maze Acq. Final Day 0.01 0.29 0.24
Morris Maze Avg. Probe 0.01 0.16 0.20
Morris Maze Probe 1 0.05 0.01 0.92
Morris Maze Probe 2 0.05 0.75 0.66
Morris Maze Probe 3 0.10 0.57 0.16
Circular Platform Avg. Errors 0.48 0.30 0.62
Circular Platform Avg. Lat. 0.14 0.13 0.04
Platform Recognition Avg. <.01 0.52 0.30
Platform Recognition Final Day <.01 0.22 0.66
RAWM Errors T1 Avg. <.01 0.79 0.22
RAWM Errors T4 Avg. 0.01 <.01 0.58
RAWM Errors T5 Avg. 0.04 0.02 0.40
RAWM Latency T1 Avg. 0.01 0.28 0.53
RAWM Latency T4 Avg. 0.01 0.04 0.30
RAWM Latency T5 Avg. 0.01 0.04 0.15
#CA = # of closed arm choices #OA = # of open arm choices
Note: Significant P values (<0.05) are highlighted in bold type and box shaded
Behavioral Measure Interaction
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comparable in behavioral performance to animals in the APP group on most tasks (except 
circular platform and elevated plus maze); it was thus added to the APP group for 
behavioral analysis of those tasks.  
 
Effects of APP and Tau Transgenicity on Sensorimotor and Anxiety-based Tasks 
  In the balance beam task (Fig. 1), both APP and Tau transgenics were impaired at 
5 months, while only the APP group was impaired in balance beam performance at 6.5 
months. Overall, the APP transgenic group was impaired between 5 and 8.5 months 
compared to Tg-, with a time x genotype interaction [F(4,30)=2.70; p<0.05]. For string 
agility, no significant group differences were observed at either 5 months or 6.5 months, 
although Tau transgenics approached impairment (p=0.065) at 6.5 months. Over both 
time points, the Tau transgenic group was nearly impaired (p=0.07) compared to NT 
mice (data not shown). 
 The 17-measure Neurologic Exam revealed no group differences, except that APP 
transgenic mice had 1) a significantly depressed pelvis during locomotion compared to 
both Tg- (p<0.0001) and Tau (p=0.022) groups, and 2) an abnormally hypotonic gait 
compared to both Tg- (p=0.049) and Tau (p=0.049) groups (data not shown).  
 No group differences in activity/exploratory behavior were observed, as tested in 
the open field at 5 months and the number of Y-maze entries at 5 months and 8.5 months 
(data not shown).  
 In elevated plus maze testing, neither transgenic group expressed higher anxiety 
that Tg- controls in any of the three measures analyzed (number of open arms entered, % 
time in open arms, and number of closed arms entered) (data not shown).  
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Figure 1. A comparison of balance beam performance by age and
transgenicity (left) and overall (right) for APP and Tau transgenic mice
and NT control mice. Balance beam performance was measured by latency to fall from the beam
apparatus over 3 successive trials. *p<0.05 compared to NT at that age (left)
or overall (right). **p<0.01 compared to NT at 5M.
*
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Although APP and Tau mice were found to be impaired in the balance beam, 
performance in all other sensorimotor tasks (including those for visual acuity) and on the 
anxiety task (with the exception of hypotonic gait and pelvic elevation in APP mice) were 
normal. Thus, neither transgenic group has generalized sensorimotor dysfunction or 
heightened anxiety that might significantly compromise performance in the cognitive-
based tasks. 
 
Effects of APP and Tau Transgenicity on Cognitive-based Tasks 
 For Y-maze % spontaneous alternation, Tg- and Tau mice improved their 
performance between the 5-month and 8.5-month test points to about 70% alternation, 
while APP mice performed at chance levels (~50%) at both ages (Fig. 2). Compared to 
Tg- mice, APP mice were nearly impaired at 8.5 months (p=0.07) and significantly 
impaired overall vs. Tg- mice (51.3±5.1% vs. 65.4±3.3%; p<0.05).  
 In Morris maze acquisition (Fig. 3), both Tg- and Tau mice nicely reduced their 
escape latencies through the 9 days of testing. By contrast, APP mice showed no 
improvement, being significantly impaired in comparison to both Tg- and Tau mice 
across all 9 days of testing (p<0.05), and especially over the last block of 3 days 
(p<0.007). Even on the final day of acquisition, APP mice continued to show 
significantly higher latencies than Tg- mice (p<0.02). A genotype x day interaction was 
also present [F(16,120)=2.55; p<0.005]. 
 During Morris maze probe trials for memory retention, Tau mice performed 
similar to Tg- mice in all three probe trials and overall (Fig. 4). However, APP mice were 
impaired on the final probe trial (Day 10) compared to Tg- mice (p<0.05). Moreover,  
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Figure 2. Y-maze percent alternation for APP and Tau transgenic
mice and NT controls at 5M and 8.5M. *p<0.05 compared to NT
overall. 
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Figure 3. A comparison of Morris water maze escape latency between
APP and Tau transgenic mice and NT controls across 9 days of 
acquisitional testing. *p<0.05 compared to NT and Tau mice over all 
9 days of testing.
*
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Figure 4. Morris water maze retention performance for APP and Tau
transgenic mice and NT controls. Retention performance is measured as
percent time spent in the goal quadrant for each of the three retention
trials (left) and overall (right). *p<0.05 or compared to NT on day 10 (left)
and compared to NT and Tau mice overall (right). 
 
 60
 
 APP mice were impaired over all three probes in comparison to both Tg- and Tau 
mice (p<0.02; Fig. 4). There were no differences in swim speed between the three groups 
(data not shown).Over the eight days of circular platform testing, no significant genotype 
effect was evident, with all three groups making a similar number of errors and having 
similar escape latencies (data not shown). 
 Across the four days of platform recognition testing, Tau mice had escape 
latencies comparable to Tg- controls (Fig. 5). By contrast, APP mice showed impaired 
recognition abilities by having higher escape latencies overall compared to Tg- mice 
(p<0.05); this impairment was particularly apparent during day 1 (vs. both Tg- and Tau 
groups; p<0.05) and during day 3 (vs. Tg-; p<0.01). Nevertheless, none of the three 
groups differed significantly on the final day of platform recognition testing.  
 Figure 6 presents the number of errors in RAWM working memory testing across 
four 3-day blocks for Trial 1 (randomized initial trial), Trial 4 (final acquisition trial), and 
Trial 5 (delayed retention trial). Tau mice performed similar to Tg- mice, although they 
made almost significantly more T4 errors vs. Tg- mice during the critical last block of 
testing (p=0.06). Compared to both Tg- controls and Tau transgenic mice, APP mice 
made significantly more working memory errors in Trial 4 of block 2, as well as in Trial 
5 during the last three blocks of testing. The T5 impairment of APP mice was so 
prevalent that a strong genotype x blocks interaction was present [F(6,42)=3.70; 
p<0.005]. 
 The impaired RAWM performance of APP mice is further underscored when 
errors are averaged over all four blocks of testing (Fig. 7). APP mice made significantly 
more T4 errors overall than Tg- controls (p<0.02) and more T5 errors overall than both 
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Figure 5. A comparision of platform recognition latency
between APP andTau transgenic mice and NT controls
across four days of testing. ** p<0.05 or higher level of
significance compared to NT and Tau on day 1 of testing.
* p<0.05 or higher level of significance compared to NT
on day 3 of testing.
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Figure 6. Radial-arm water maze errors for APP and Tau transgenic mice and NT
control mice across four 3-day blocks of testing for T1, T4, and T5. *p<0.05 or 
higher level of significance compared to both NT and Tau mice for that particular
block and trial.
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Figure 7. A comparison of radial-arm water maze errors
for T1, T4, and T5 in APP and Tau transgenic mice and
NT controls across 12 days of testing. *p<0.05 compared
to NT controls. **p<0.01 compared to NT and Tau mice.
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Tg- and Tau mice (p<0.01). APP mice were unable to improve their overall working 
memory performance from T1 through T5 (Fig. 7), whereas both Tg- and Tau mice were  
able to substantially reduce their number of errors over the same overall trials. Statistical 
evaluation of RAWM latency measures revealed very similar results to those obtained by 
analysis of RAWM errors (data not shown.) 
 
Factor Analysis 
 Factor analysis of behavioral measures was performed to determine the 
underlying relationships between tasks. Table 3 indicates the task/measure loadings when 
all 39 behavioral measures were included in the analysis. Five principle factors were 
obtained. Measures for RAWM, platform recognition, and Morris maze acquisition 
loaded heavily under Factor 1, which accounted for more variance (25.2%) than any 
other factor. This factor encompassed multiple cognitive domains, including working 
memory, recognition, and reference learning. Morris maze memory retention loaded 
independently on Factor 5, indicating an independent loading of reference memory 
separate from other cognitive domains. Measures from two other cognitive-based tasks, 
circular platform and Y-maze spontaneous alternation, also loaded on factors separate 
from Factor 1. Factor 2 loaded balance beam and string agility measures, indicating this 
factor’s sensorimotor basis, specifically involving balance/agility.  
 Similar factor loadings were obtained when a subset of 19 measures was used in 
the factor analysis (Table 3). The 19-measure subset (which omits all intermediate 
measures, redundant RAWM latency measures, and elevated plus maze measures) has 
been used routinely in our prior studies (Leighty et al., 2002). For the six primary factors 
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Table 3: Task loadings resulting from 39- and 19- measure factor analysis involving
              all rd- animals (n=18)
Factor 39 Measures 19 Measures
I (25.2) (25.0)
RAWM working memory RAWM working memory
Platform Recognition Platform Recognition
Morris Maze acquisition Morris Maze acquisition
II (16.1) (16.4)
Balance Beam Circular platform
String Agility (errors and latency)
III (13.8) (15.8)
Y-maze (% Alt. and entries) Open Field activity
Circular platform (errors)
IV (10.1) (9.5)
Circular platform (latency) Balance Beam
Elevated Plus-Maze (O.A.)
V (7.6) (7.9)
Morris Maze retention String Agility
VI (6.8)
--------- Morris Maze retention
O.A. = # of open arm entries and time spent in open arms
Numbers in parentheses are percent of total variance explained
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obtained, Factor 1 was again heavily based on cognitive domains provided by measures 
in the RAWM, platform recognition, and Morris maze tasks. Also consistent with the 39- 
measure analysis, Morris maze reference memory and circular platform measures loaded 
independently and separate from the primary cognitive factor (Factor 1). However, 
balance and agility measures had separate loadings for the 19-measure data set.  
 
Discriminant Function Analysis (DFA) 
 To determine whether the behavioral performance of the three groups (NT, Tau, 
and APP) could be used to distinguished them from one another, Discriminant Function 
Analysis (DFA) was performed (Table 4). The same behavioral measures were included 
as for Factor Analysis, except that the four circular platform and three elevated plus maze 
measures were omitted.* For the resulting 32- and 15-measure data sets, the direct entry 
DFA method (which includes all measures) could not discriminate between the three 
groups based on their behavior. In sharp contrast, the step-wise forward DFA method 
(which selects measures based on their contribution to variance) was highly effective in 
completely discriminating between all three groups using either 32- or 15-measure data 
sets (Table 4). For both step-wise forward DFA analyses, 8 measures provided maximal 
discriminablilty. These distinguishing measures were mostly cognitive-based, being taken 
from RAWM, Morris maze, and platform recognition tasks. Thus, these tasks are 
particularly important, and sufficient, to behaviorally distinguish between all three 
groups.  
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Table 4: 15- and 32-measure discriminant function analysis of Tg-, APP, and Tau groups 
Measures Direct Entry Method 
(All measures used) Significance Measures Used
RAWM B4T4 errors
RAWM T5 errors (average)
Morris Maze acquisition (Final Day)
Morris Maze retention (average)
Platform Recognition (Final Day)
Platform Recognition (average)
Balance Beam
String Agility (average)
RAWM B4T4 errors
RAWM T5 latency (average)
Morris Maze retention (Day 7)
Platform Recognition (Final Day)
Platform Recognition (average)
Balance Beam
String Agility (average)
Open Field
*Significant p values are for Wilks' lambda, designating overall discrimination between the 3 groups 
(Tg-, APP, and Tau). Post-hoc pair-wise comparisons were all significant at p<0.05 or greater level of
significance, thus providing complete discrimination between the two groups. 
p<.0005*Not Discriminable32
Step-wise Forward Method
15 Not Discriminable p<.0001*
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*These two tasks were omitted because behavioral scores of the single APP+Tau mouse 
included in the APP group were not cons istent with other APP animals in the these two 
tasks. Omission of this animal’s data from these two tasks would have eliminated all of  
that animal’s data from the other tasks for DFA. As well, neither task showed genotypic 
differences in performance.  
 
Correlations Between Cognitive Performance and Tau Pathology 
 For the Tau transgenic group alone (n=7), a number of significant correlations 
were found between cognitive performance in the three water-based tasks and the number 
of Tau+ neurons in the neocortex and hippocampus (Table 5). Escape latencies during the 
final day of Morris maze acquisition and in both platform recognition measures were 
highly correlated with Tau+ neurons numbers in neocortex. Thus, poorer performance in 
both tasks correlated with increased number of Tau+ neurons. Moreover, RAWM T5 
errors in the final block and overall T5 latency, as well as overall platform recognition 
latency, correlated with Tau+ neurons in hippocampus. Thus, poorer working memory 
(RAWM) and recognition correlated with increased numbers of Tau+ hippocampus 
neurons. Three examples of these correlations are depicted in Figure 8.  
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Table 5: Correlations between number of Tau+ neurons and cognitive performance in Tau 
             transgenic mice (N=7) ("p" values indicated for significant correlations)
Tau+ Neurons Tau+ Neurons Tau+ Neurons
in Neocortex in Hippocampus in Whole Brain
RAWM latency (T5 average)
Behavioral Measure
0.025
0.000
Platform Recognition Latency (Last day)
RAWM errors (Last Block, T5)
Morris Maze Latency (Last day)
Platform Recognition Latency (overall)
0.016
0.000
n.s.
0.013
n.s.
0.036
0.012
n.s.
n.s.
0.007
n.s.
n.s. 0.022
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Correlations Between Number of Tau+ Neurons
 and Cognitive Deficits in P301L Mice
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Figure 8. Graphs indicating the significant
correlations between number of tau+ neurons in
cerebral cortex and hippocampus of P301L
mouse brains and cognitive behavior measures
in the three water-based tasks. Significant r
values and p values for the correlations are listed.
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Discussion 
 
General Summary 
 The results of this study indicate that retinal degeneration seriously impairs the 
performance of mice in behavioral tasks requiring good vision. Animals that carry the 
homozygous allele of this mutation must, therefore, be eliminated from any such study 
requiring visual acuity. Young APP mice were found to be impaired in several cognitive 
tasks, including platform recognition, Morris maze, and Y-maze, as early as 5.5 months 
of age. These mice were, however, found to have fairly normal sensorimotor function, 
demonstrating significant impairment only in balance beam performance starting at 5 
months. P301L mutant tau mice were not found to possess significant impairments in any 
sensorimotor or cognitive tasks through 8.5 months of age. Factor analysis was 
successfully able to group those behavioral measures that shared the most in common and 
contributed the most variance to the behavioral data. Likewise, discriminant function 
analysis (DFA) was able to accurately discriminate between the three transgenic groups 
of mice using only an 8-measure data set. Finally, the use of correlation analysis 
demonstrated an association between the formation of NFT’s in cortex and hippocampus 
and cognitive impairments in P301L mice. 
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Effects of Retinal Degeneration 
 Through the use of genotyping, it was determined that most of the 32 animals 
selected for this study were either unaffected carriers (rd/+) of the rd gene or homozygous 
recessive (rd/rd), predisposed to developing retinal degeneration. A significant number of 
animals from each transgenic line were (rd/rd) and thus suffered from retinal 
degeneration. To determine the extent to which retinal degeneration played a part in the 
behavioral impairment of these animals, all subjects’ behavioral scores were assessed 
using both genotype and rd status as independent grouping variables. Performance in 
several behavioral tasks, including Morris water maze, platform recognition, and radial-
arm water maze, were negatively affected by retinal degeneration. These findings 
illustrate that poor vision, caused in this case by the retinal degeneration (rd) gene, 
significantly impairs behavioral performance in those tasks that require keen vision. 
Performance in sensorimotor tasks, such as balance beam, string agility, and open field, 
which require less visual acuity, failed to demonstrate any significant correlation with 
retinal degeneration. Spatial acquisition tasks, such as Morris water maze, platform 
recognition, and RAWM, which require visual acuity, demonstrated the most significant 
impairments due to the rd gene. These findings agree with the results obtained by 
Spencer et al. (1995), indicating that retinally-degenerate aged rats, albeit not caused by a 
genetic mutation, had behavioral impairment in the Morris water maze (a spatial 
acquisition task). A study conducted by Fuller et al. (1973) found, however, that rd/rd 
mice showed no impairment in a spatial water T-maze that required that test subjects 
locate an escape ladder found in one of the two swim arms. The authors suggest that 
these results may be an indication that spatial cues are not a significant component of 
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learning in this task. These results are in agreement with our findings that the rd mutation 
does not significantly affect performance in the Y-maze spontaneous alternation task, a 
similar task that requires cognitive function with limited visual acuity. Curiously, my 
findings contradict the results obtained by Cook et al. (2001), who reported that rd/rd 
mice show less anxiety when placed in an elevated zero maze, preferring to spend more 
time in the open arms of the maze than the closed arms. My findings indicate no 
significant difference between rd/rd mice and mice with normal vision (+/+ and rd/+) in 
the amount of time spent in the open arms or the number of open arm entries made in the 
elevated plus maze, a similar task used to measure anxiety.  
 Because rd/rd test subjects were found to have significant impairments in various 
tasks, irrespective of transgenicity, all such animals were excluded from further statistical 
analysis. The elimination of these rd/rd mice reduced the number of experimental animals 
from 32 to 18: 7 Tg- mice, 7 Tau mice, 3 APP mice, and only a single Tau+APP mouse. 
The performance of the single TAPP mouse did not significantly differ from the 
performance of the remaining three APP mice in all tasks except circular platform and 
elevated plus maze, therefore it was grouped with the APP mice for the purposes of 
statistical analyses.  
 
Effects of APP and Tau Transgenicity on Sensorimotor and Anxiety-Based Tasks 
 To assess levels of anxiety and sensorimotor function in transgenic and non-
transgenic mice, all test subjects were evaluated in a variety of tasks. According to my 
findings, neither of the two transgenic groups showed differences in exploratory behavior 
compared to Tg-, as measured by activity in the open field task and the number of entries 
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made in the Y-maze spontaneous alternation task. These observations are in agreement 
with the findings put forth by Holcomb et al., (1999), indicating that APP mice are not 
significantly different from Tg- in their number of Y-maze entries at 6 and 9 months. 
King and Arendash (2002a) reported that APP mice are more active in the open field, 
compared to Tg-, at 3 months of age, but not at 9 months. My findings, which involve an 
intermediate time point, indicate that APP mice are not more active in the open field at 5 
months compared to Tg-. 
Both transgenic lines did, however, experience some impairment in the balance 
beam and string agility tasks. When evaluated at 5 months of age, both the APP and Tau 
groups had significant impairment in the balance beam when compared to Tg-, while 
only the APP mice exhibited similar impairments when the animals were re-tested at 6.5 
months of age. Neither transgenic group showed impairments at the final time point of 
8.5 months. Overall, the APP mice were significantly impaired in their balance beam 
performance when compared to Tg-, while the performance of the Tau mice was not 
significantly different from control. While neither transgenic group had statistically 
significant deficits in string agility, the Tau group did exhibit nearly-significant 
impairments in string agility at 6.5 months of age (p=0.065) and overall (p=0.07), 
compared to Tg-. King and Arendash (2002a) agree with my observation that APP mice 
are impaired in the balance beam at an early age. The authors found that APP mice are 
impaired in balance beam at 3, 14, and 19 months of age, but not at 9 months, while my 
observations indicate that APP mice are impaired at 5 and 6.5 months of age, but not at 
8.5 months. In addition, King and Arendash (2002a) indicate that APPsw and Tg- mice 
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are not significantly different in string agility at 3 and 9 months of age, which agrees with 
my observation that APP mice are not impaired in string agility at 5 or 6.5 months of age. 
Neither group experienced heightened anxiety as evidenced by the fact that both 
the APP and Tau groups spent similar amounts of time in the open arms of the elevated 
plus maze and made a similar number of open arm choices compared to Tg-.  
Finally, the 17-Measure neurologic screen revealed that APP mice suffered from a 
mild hypotonic gait and slightly depressed pelvis. Neither of these conditions, however, 
precluded the APP mice from performing in any of the behavioral tasks. 
 While little is known regarding the behavioral impairments associated with 
mutations to the tau protein that lead to NFT formation, there are a few significant 
findings that relate to the observations made in this paper. Lewis et al., (2000) report that 
P301L mice display severe sensorimotor deficits as early as 4.5 months of age in 
homozygous animals and beginning at 6.5 months in hemizygotes. These deficits include 
the lack of an escape extension during tail elevation, spontaneous back paw clenching 
while standing, a delayed righting response, an inability to hang from a suspended string 
for more than a few seconds, and decreased grooming, weight, and mobility. While my 
study did not address such variables as body weight and grooming, the observations made 
during an extensive array of sensorimotor tasks reflect the relatively normal function of 
all Tau mice through the 5 to 8.5 month test period. As discussed previously, all Tau 
mice in this study displayed normal ambulation and activity, as well as proper 
sensorimotor function and neurological response to stimulation. Moreover, Tau mice, as a 
group, performed similar to Tg- controls on all behavioral measures analyzed during the 
test period. Tanemura et al., (2002) reported that V337M mice, which form hippocampal 
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NFT’s as early as 11 months, show increased locomotion in the open field tasks and 
elevated plus maze and spent more time in the open arms of the elevated plus maze at 11 
months of age. While these observations involve a different transgenic line and different 
age group from the animals used in my study, they still form a critical basis for 
comparison. As discussed earlier, the P301L mice evaluated in my study showed no 
differences in their level of activity or anxiety compared to Tg-. It must be noted, 
however, that the V337M mutation results in more extensive NFT formation and less 
profound cell death than the P301L mutation. Additionally, the V337M transgenic line 
produces NFT’s almost exclusively in the hippocampal region, unlike the P301L line, 
which generates abnormal tau in the hindbrain and brain stem as well as the 
hippocampus, predisposing the animal to potential sensorimotor deficits. Tatebayashi et 
al., (2002) observed sensorimotor and cognitive function in 16-23 month-old R406W tau 
mutant mice, a transgenic line that produces forebrain NFT’s beginning at approximately 
18 months. In the study, Tatebayashi et al. observed that these mice display normal 
physical characteristics, sensorimotor reflexes, and motor coordination, compared to Tg-. 
These findings, albeit based on a different line of tau mutant at a different age, is in 
agreement with the results obtained in my study. 
 
Effects of APP and Tau Transgenicity on Cognitive-based Tasks 
 To determine the cognitive deficits associated with the APPsw and P301L 
transgenic lines, transgenic and non-transgenic mice were evaluated in a variety of 
cognitive-based tasks. In Y-maze percent spontaneous alternation, APP mice were very 
nearly impaired (p=0.07) vs. Tg-, in their ability to spontaneously alternate between the 
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three arms of the maze at 8.5 months of age. Overall, the APP group was impaired, 
compared to Tg-, in the percent alternation task, while Tau mice show no significant 
deficits in this task. A study by Hsaio et al. (1996) indicate that APP mice are unimpaired 
at 3 months of age in Y-maze spontaneous alternation, but develop impairments at 10 
months of age. These results agree with the findings from my study, indicating that APP 
mice are nearly impaired at 5 and 8.5 months of age and impaired overall for both time 
points. Also consistent with my findings, Holcomb et al., (1999) studied the performance 
of APP mice in the Y-maze spontaneous alternation task and found that they develop 
significant impairments at 6 months. A study performed by King and Arendash (2002a) 
revealed that APP mice develop deficits in Y-maze alternation as early as 3 months of 
age, but not at 9 months of age. King and Arendash do, however, report an overall Y-
maze impairment from 3 to 19 months of age. 
The Morris water maze acquisition test, which requires that mice learn the 
location of a static, submerged platform over a period of nine days, also revealed 
cognitive deficits in the APP group. In this task, the APP mice had a significantly longer 
latency, compared to Tg- and Tau, to locate the hidden platform on the final day of 
acquisition (day 9), as well as overall. Tau mice showed no impairments in locating the 
platform. The memory retention phase of this task (which occurred prior to acquisition 
testing on days 4 and 7, and following the last day of acquisition on day 10) evaluated 
mice on their ability to search for the escape platform after the platform had been 
removed from the pool. Animals that spend the most time in the goal quadrant, which 
formerly contained the escape platform, are said to demonstrate superior memory 
retention. While both transgenic groups performed similarly to Tg- on days 4 and 7, the 
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APP mice demonstrated a significant impairment in memory retention in the final 
retention trial (day 10) compared to Tg-. In addit ion, APP mice also exhibited an overall 
impairment in memory retention compared to Tau and Tg- groups across all three 
retention trials. These acquisition and retention impairments in APP mice cannot be 
explained by each mouse’s swim agility, as all groups of mice were found to swim at 
approximately the same speed when placed in the pool. Hsaio et al., (1996) found that 
Tg2576 mice show no impairments in Morris water maze acquisition or retention at 2 or 
6 months of age, but begin to exhibit such impairments at 9-10 months. The results of my 
study indicate that APP mice are, in fact, impaired in Morris water maze acquisition and 
retention as early as 5.5 months of age. It must be noted, however, that Hsaio et al. 
employed APPsw mice with a Tg2576 background, while my study involved APPsw 
mice with a more mixed strain background. Further, Westerman et al. (2002) conclude 
that Tg2576 mice develop impairments in Morris water maze acquisition and retention 
beginning at 6 to 11 months. In contrast, Koistinaho et al. (2001) report that APP mice 
are impaired in Morris water maze much earlier--as early as 3 months of age. In their 
comprehensive behavioral study of APP mice, King and Arendash (2002a) find that Tg+ 
mice possess no performance deficits in water maze acquisition and retention through 19 
months of age, compared to Tg-. 
APP mice were also found to be impaired in the platform recognition task, 
requiring animals to swim to a clearly visible, raised platform, whose location changes 
throughout the four trials of daily testing. Overall, APP mice required a significantly 
greater amount of time to locate and mount the visible platform than Tg-. Specifically, 
the APP mice performed worse in the platform recognition task than either Tau or Tg- 
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mice on the first day of testing, and demonstrated longer latencies on day 3, compared to 
Tg- only. Curiously, the APP group of mice did not demonstrate an impairment to locate 
the platform on the final day of testing, often described as the best indicator of task 
performance. This result may be an indication that APP mice are slow in their ability to 
change their search strategy. Unlike the Morris water maze, which requires that mice 
memorize the spatial location of a fixed hidden platform, the platform recognition task 
demands that mice be able to track the changing locations of a visible platform in the 
same pool. Tau mice were not significantly impaired compared to Tg- in this task. King 
and Arendash (2002a) found that Tg2576 mice are impaired in the platform recognition 
task at 9 months and beyond. My data indicates that impairment in platform recognition 
occurs much sooner in APP mice, as early as 6 months of age. 
The radial-arm water maze (RAWM) was also used to assess cognitive function in 
this study. RAWM is a sensitive task that assesses working memory. In daily testing, 
working memory is most evident on the last of the four successive acquisition trials (T4) 
and the delayed retention trial (T5), which occurs 30 minutes after completion of trial 4. 
Unlike the Morris water maze, where the location of the platform remains constant 
throughout the nine days of testing, the RAWM task employs a semi-random sequence to 
rotate the platform between each of the six swim arms for each day of testing. This 
unique facet of the RAWM task is what requires the use of working memory. The 
RAWM task also requires spatial reference of external cues, as does the Morris water 
maze, to locate the hidden platform. When mice were evaluated across the 12 days of 
testing, APP mice were found to exhibit an “overall” impairment on T4 and T5 in 
locating the hidden platform, compared to Tg-, indicating working memory impairment. 
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When the 12 days of RAWM testing were analyzed separately in four 3-day blocks, APP 
mice were found to make more errors than Tg- and Tau in T5 for blocks 2, 3, and 4, as 
well as T4 in block 2. APP and Tau mice were also nearly impaired vs Tg- in T4 for 
block 4. Although not reported here, similar results were obtained for RAWM latency. 
Despite the wealth of information concerning the cognitive impairments of APP mice, 
there is no published data describing the performance of these mice in radial-arm water 
maze. A study by Arendash et al. (2001) did, however, describe the performance of 
APPsw+PS-1 mice in the radial-arm water maze task at both 5-7 and 15-17 months of 
age. The study found that these mice showed no impairments in T4 performance at either 
time point but did display impairments in T5 at 15-17 months.  
Finally, circular platform, a cognitive task that incorporates stress and anxiety, 
revealed no significant impairments for either transgenic group compared to Tg-. King 
and Arendash (2002a) are in agreement with my results concerning the circular platform 
task, concluding that APP mice are unimpaired in this task through 19 months of age.  
Currently, very little is known with regards to the cognitive impairments incurred 
by mutations to the tau protein. Tanemura et al. (2001) do report, however, that V337M 
tau mutants are unimpaired in the Morris water maze at 11 months of age. These results 
are in agreement with the findings described in my study, indicating that P301L tau mice, 
as a group, are unimpaired in all cognitive tasks. A study by Tatebayashi et al. (2002) 
found that R406W tau mutants are impaired in the contextual and cued fear condition 
tasks, measures of associative memory. Thus far, this is the only published evidence that 
any mutation to tau is capable of generating cognitive impairments in animal models of 
Alzheimer’s disease.  
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Factor Analysis 
 Factor analysis is a very powerful tool used in statistics that has the ability to 
evaluate a large data set, determine which measures contribute the most variance to the 
data set, and what the underlying relationship is between these measures. In this study, 
factor analysis was used to group all 39 behavioral measures into common factors, each 
contributing to the variance of the behavioral data set. Each factor contains behavioral 
measures that are related to one another. Behavioral measures that are grouped into the 
same factor are therefore assessing a similar component of behavior (i.e.: sensorimotor 
function, working memory, etc.). Through the use of factor analysis, we can infer the 
relationship between multiple tasks, and predict how performance in one task might be 
predictive of performance in another task. In this study, two separate factor analyses were 
performed, one using the entire 39-measure data set, the second using a more selective 
19-measure data set. The results of the factor analysis indicate that the RAWM working 
memory task, platform recognition task, and Morris water maze acquisition task share a 
lot in common, as they all load together under factor 1. These three tasks each serve as 
indicators of unique aspects of cognitive function, including working memory, 
recognition, and reference learning. Balance beam and string agility also loaded together, 
under factor 2 for the 39-measure analysis, illustrating how these two tasks both serve as 
measures of balance and agility. Y-maze spontaneous alternation and circular platform 
also loaded together (factor 3 of the 39-measure analysis), underscoring the cognitive-
based properties of these two tasks. In each analysis, Morris maze retention loaded 
independently, indicating the unique nature of reference memory from all other cognitive 
measures.  
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 While factor analysis is a fairly common statistical tool in various scientific and 
mathematical fields, it is still a novel concept in the realm of behavioral analysis. As 
such, there is little precedent for this type of ana lysis in Alzheimer’s transgenics. While 
King et al. (1999) were the first to utilize factor analysis to determine which behavioral 
measures relate to one another, the factor analysis employed in their study was “rotated” 
and only task (not measure) loadings were reported. Based on my findings, therefore, I 
believe that factor analysis has the potential to further explain the complex relationships 
between the tasks currently used to evaluate sensorimotor and cognitive function in 
transgenic mice.  
 
Discriminant Function Analysis 
 Like factor analysis, discriminant function analysis (DFA) is a powerful statistical 
tool that has recent ly been introduced into behavioral analysis. DFA works by evaluating 
multiple data sets to determine whether the data sets can be discriminated from one 
another and which measures are best able to distinguish them. In this study, DFA was 
used to evaluate the behavioral data from the three groups analyzed (Tg-, APP, and Tau) 
to determine whether they could be completely discriminated and, if so, which behavioral 
measures can best discriminate between the three groups. Two DFA methods were used 
in this study, the direct-entry method and the stepwise-forward method. In addition, for 
each method, two separate analyses were run, one with the entire dataset, and the other 
with only 15 behavioral measures. The direct entry method utilizes all behavioral 
measures in the DFA model, while the stepwise-forward method selects measures one at 
a time, keeping only those variables that are best able to discriminate between the three 
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groups in the final model. The results of the DFA analysis indicate that the direct entry 
method was unable to discriminate between the three transgenic groups. The stepwise 
forward method, however, was able to discriminate between the three groups using only 
eight behavioral measures. The 15- and 32-measure stepwise DFA models each arrived at 
a set of eight measures, with both sets having most of these behavioral measures in 
common. In both analyses, cognitive measures, including RAWM working memory, 
Morris water maze, and platform recognition, were found to be critical in discriminating 
between the three groups. Certain sensorimotor tasks, such as open field activity, balance 
beam, and string agility, were also found to be important in discriminating between Tg-, 
Tau and APP groups.  
 DFA, like factor analysis, is still a very new concept in behavioral analysis and, as 
a result, has no precedent in Alzheimer’s transgenics. Like factor analysis, however, DFA 
appears to hold great promise for inclusion in future behavioral studies. DFA has the 
potential to eliminate the need for large behavioral test batteries, instead selecting a small 
subset of behavioral measures that are equally capable of discriminating between various 
transgenic groups. In this way, less time and effort would be needed to accurately 
evaluate the sensorimotor and cognitive function of transgenic mice and the effects of 
therapeutics therein. Before DFA can be used with great accuracy in a wide variety of 
behavioral studies, however, it must be studied further to determine how its precision 
holds up with different transgenic lines and various age groups. In the future, DFA may 
be instrumental in the development of better behavioral test batteries.  
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Correlations Between Behavioral Performance and Tau Pathology 
 In order to create a link between the biochemical and pathological changes that 
take place in the brains of tau mutant mice with their associated sensorimotor and 
cognitive deficits, a correlational analysis was performed. In the analysis, five measures 
of tau pathology were used as biochemical markers: number of tau+ neurons in the 
brainstem, cortex, hippocampus, amygdala, and whole brain. These five pathological 
measures were entered into a correlational matrix with the 39 behavioral measures 
discussed previously. The results of the analysis indicate that tau pathology is exclusively 
correlated with deficits in cognitive function, particularly in the swimming tasks. An 
increased number of tau+ neurons in the whole brains of P301L mice was found to be 
correlated with impaired performance on the final day of Morris maze acquisition and 
platform recognition, as well as overall performance in platform recognition. When the 
number of cortical tau+ neurons was correlated with behavioral impairments, these same 
relationships were seen, indicating the critical nature of the cortex in cognitive function. 
The amount of hippocampal tau was found to be correlated with performance in the 
platform recognition and radial-arm water maze tasks, specifically T5 errors in the final 
block of testing and overall T5 latency, two measures of working memory. This finding 
seems to illustrate the function of the hippocampus in working memory and spatial 
acquisition. There were no significant correlations between behavioral performance and 
tau pathology in the brainstem and amygdala, indicating the relative unimportance of 
these two brain regions in cognitive function. While brainstem tauopathy has been linked 
to sensorimotor deficits in other Tau studies, the relative lack of any such correlation in 
this study, coupled with the absence of any significant sensorimotor deficits, indicates 
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that tauopathy present in the brainstem during the behavioral testing period was not 
detrimental to cognitive or sensorimotor performance.  
 As discussed previously, there are only a small number of studies that have 
attempted to characterize the behavioral impairments associated with tau mutations. Of 
the few studies that have been carried out, none of these has utilized a comprehensive test 
battery to assess sensorimotor and cognitive deficits. As a result, there is no precedent for 
the type of correlational analysis that is described in this study. Based on these findings, 
however, we can conclude that a strong correlation exists between the formation of 
NFT’s in the hippocampus/cortex and behavioral impairment. The fact that the P301L 
mice observed in this study failed to show any significant cognitive or sensorimotor 
impairments between 5 and 8.5 months of age illustrates that these mice, as a group, did 
not develop extensive enough NFT formations during the age range eva luated to generate 
such impairments in all mice. However, NFT formation in individual animals (those 
further along in forebrain tauopathy), was associated with, and likely causative to, 
cognitive impairment in three tasks. Unfortunately, the presence of extensive NFT’s in 
the hindbrain and brainstem of these P301L mice results in premature hind limb paralysis 
and death, precluding the assessment of behavioral impairment in these mice beyond 9 
months. If such an evaluation were possible, however, it would be expected that P301L 
mice, as a group, would become significantly impaired in cognitive tasks beyond 9 
months of age, corresponding with an increase in the number of cortical and hippocampal 
NFT’s.  
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 In summary, the results of this study indicate that APP mice are cognitively-
impaired at a young age, as early as 5.5 months old, while appearing to be largely devoid 
of any debilitating sensorimotor deficits through the same time frame. Conversely, tau 
(P301L) mutants are found to have no significant sensorimotor or cognitive impairments 
through 8.5 months of age.  
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